Companies: 11,246     total market cap: $155.360 T
โ‚ฌEUR๐Ÿ‡ช๐Ÿ‡บโ‚นINR๐Ÿ‡ฎ๐Ÿ‡ณยฃGBP๐Ÿ‡ฌ๐Ÿ‡ง$CAD๐Ÿ‡จ๐Ÿ‡ฆ$AUD๐Ÿ‡ฆ๐Ÿ‡บ$NZD๐Ÿ‡ณ๐Ÿ‡ฟ$HKD๐Ÿ‡ญ๐Ÿ‡ฐ$SGD๐Ÿ‡ธ๐Ÿ‡ฌ
DaVita
DVA
#1849
Rank
$11.79 B
Marketcap
๐Ÿ‡บ๐Ÿ‡ธ United States
Country
$183.77
Share price
1.72%
Change (1 day)
42.40%
Change (1 year)
โš•๏ธ Healthcare
Categories
DaVita Inc. is an American company providing dialysis services for patients with chronic and acute kidney failure.
  1. DaVita
  2. Quarterly Reports (10-Q)
  3. Financial Year FY2026 Q2

DaVita - 10-Q quarterly report FY2026 Q2


Text size:
false2026Q2000092706612/3110.0010.0015,0005,000——0.0010.001450,000450,00063,95568,54969,19868,5495,243—1,750,00012/31/202512/31/2027750,000750,00012/31/202512/31/2027250,0001,000,00012/31/202612/31/2028250,0002,244,778five yearsxbrli:sharesdva:TheNumberOfReportableSegmentsiso4217:USDiso4217:USDxbrli:sharesdva:segmentxbrli:pure00009270662026-01-012026-06-3000009270662026-07-3100009270662026-04-012026-06-3000009270662025-04-012025-06-3000009270662025-01-012025-06-3000009270662026-06-3000009270662025-12-3100009270662024-12-3100009270662025-06-300000927066dva:TemporaryEquityRedeemableNoncontrollingInterestsMember2026-03-310000927066us-gaap:CommonStockMember2026-03-310000927066us-gaap:AdditionalPaidInCapitalMember2026-03-310000927066us-gaap:RetainedEarningsMember2026-03-310000927066us-gaap:TreasuryStockCommonMember2026-03-310000927066us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310000927066us-gaap:ParentMember2026-03-310000927066us-gaap:NoncontrollingInterestMember2026-03-310000927066dva:TemporaryEquityRedeemableNoncontrollingInterestsMember2026-04-012026-06-300000927066us-gaap:RetainedEarningsMember2026-04-012026-06-300000927066us-gaap:ParentMember2026-04-012026-06-300000927066us-gaap:NoncontrollingInterestMember2026-04-012026-06-300000927066us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300000927066us-gaap:CommonStockMember2026-04-012026-06-300000927066us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300000927066us-gaap:TreasuryStockCommonMember2026-04-012026-06-300000927066dva:TemporaryEquityRedeemableNoncontrollingInterestsMember2026-06-300000927066us-gaap:CommonStockMember2026-06-300000927066us-gaap:AdditionalPaidInCapitalMember2026-06-300000927066us-gaap:RetainedEarningsMember2026-06-300000927066us-gaap:TreasuryStockCommonMember2026-06-300000927066us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300000927066us-gaap:ParentMember2026-06-300000927066us-gaap:NoncontrollingInterestMember2026-06-300000927066dva:TemporaryEquityRedeemableNoncontrollingInterestsMember2025-12-310000927066us-gaap:CommonStockMember2025-12-310000927066us-gaap:AdditionalPaidInCapitalMember2025-12-310000927066us-gaap:RetainedEarningsMember2025-12-310000927066us-gaap:TreasuryStockCommonMember2025-12-310000927066us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310000927066us-gaap:ParentMember2025-12-310000927066us-gaap:NoncontrollingInterestMember2025-12-310000927066dva:TemporaryEquityRedeemableNoncontrollingInterestsMember2026-01-012026-06-300000927066us-gaap:RetainedEarningsMember2026-01-012026-06-300000927066us-gaap:ParentMember2026-01-012026-06-300000927066us-gaap:NoncontrollingInterestMember2026-01-012026-06-300000927066us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-06-300000927066us-gaap:CommonStockMember2026-01-012026-06-300000927066us-gaap:AdditionalPaidInCapitalMember2026-01-012026-06-300000927066us-gaap:TreasuryStockCommonMember2026-01-012026-06-300000927066dva:TemporaryEquityRedeemableNoncontrollingInterestsMember2025-03-310000927066us-gaap:CommonStockMember2025-03-310000927066us-gaap:AdditionalPaidInCapitalMember2025-03-310000927066us-gaap:RetainedEarningsMember2025-03-310000927066us-gaap:TreasuryStockCommonMember2025-03-310000927066us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310000927066us-gaap:ParentMember2025-03-310000927066us-gaap:NoncontrollingInterestMember2025-03-310000927066dva:TemporaryEquityRedeemableNoncontrollingInterestsMember2025-04-012025-06-300000927066us-gaap:RetainedEarningsMember2025-04-012025-06-300000927066us-gaap:ParentMember2025-04-012025-06-300000927066us-gaap:NoncontrollingInterestMember2025-04-012025-06-300000927066us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300000927066us-gaap:CommonStockMember2025-04-012025-06-300000927066us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300000927066us-gaap:TreasuryStockCommonMember2025-04-012025-06-300000927066dva:TemporaryEquityRedeemableNoncontrollingInterestsMember2025-06-300000927066us-gaap:CommonStockMember2025-06-300000927066us-gaap:AdditionalPaidInCapitalMember2025-06-300000927066us-gaap:RetainedEarningsMember2025-06-300000927066us-gaap:TreasuryStockCommonMember2025-06-300000927066us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300000927066us-gaap:ParentMember2025-06-300000927066us-gaap:NoncontrollingInterestMember2025-06-300000927066dva:TemporaryEquityRedeemableNoncontrollingInterestsMember2024-12-310000927066us-gaap:CommonStockMember2024-12-310000927066us-gaap:AdditionalPaidInCapitalMember2024-12-310000927066us-gaap:RetainedEarningsMember2024-12-310000927066us-gaap:TreasuryStockCommonMember2024-12-310000927066us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000927066us-gaap:ParentMember2024-12-310000927066us-gaap:NoncontrollingInterestMember2024-12-310000927066dva:TemporaryEquityRedeemableNoncontrollingInterestsMember2025-01-012025-06-300000927066us-gaap:RetainedEarningsMember2025-01-012025-06-300000927066us-gaap:ParentMember2025-01-012025-06-300000927066us-gaap:NoncontrollingInterestMember2025-01-012025-06-300000927066us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-06-300000927066us-gaap:CommonStockMember2025-01-012025-06-300000927066us-gaap:AdditionalPaidInCapitalMember2025-01-012025-06-300000927066us-gaap:TreasuryStockCommonMember2025-01-012025-06-300000927066dva:MedicareandMedicareAdvantageMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-04-012026-06-300000927066dva:MedicareandMedicareAdvantageMember2026-04-012026-06-300000927066dva:MedicareandMedicareAdvantageMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-04-012025-06-300000927066dva:MedicareandMedicareAdvantageMember2025-04-012025-06-300000927066dva:MedicaidandManagedMedicaidMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-04-012026-06-300000927066dva:MedicaidandManagedMedicaidMember2026-04-012026-06-300000927066dva:MedicaidandManagedMedicaidMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-04-012025-06-300000927066dva:MedicaidandManagedMedicaidMember2025-04-012025-06-300000927066dva:OtherGovernmentPayorsMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-04-012026-06-300000927066dva:OtherGovernmentPayorsMemberus-gaap:AllOtherSegmentsMember2026-04-012026-06-300000927066dva:OtherGovernmentPayorsMember2026-04-012026-06-300000927066dva:OtherGovernmentPayorsMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-04-012025-06-300000927066dva:OtherGovernmentPayorsMemberus-gaap:AllOtherSegmentsMember2025-04-012025-06-300000927066dva:OtherGovernmentPayorsMember2025-04-012025-06-300000927066dva:CommercialPayorsMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-04-012026-06-300000927066dva:CommercialPayorsMemberus-gaap:AllOtherSegmentsMember2026-04-012026-06-300000927066dva:CommercialPayorsMember2026-04-012026-06-300000927066dva:CommercialPayorsMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-04-012025-06-300000927066dva:CommercialPayorsMemberus-gaap:AllOtherSegmentsMember2025-04-012025-06-300000927066dva:CommercialPayorsMember2025-04-012025-06-300000927066dva:MedicareandMedicareAdvantageMemberus-gaap:AllOtherSegmentsMember2026-04-012026-06-300000927066dva:MedicareandMedicareAdvantageMemberus-gaap:AllOtherSegmentsMember2025-04-012025-06-300000927066dva:MedicaidandManagedMedicaidMemberus-gaap:AllOtherSegmentsMember2026-04-012026-06-300000927066dva:MedicaidandManagedMedicaidMemberus-gaap:AllOtherSegmentsMember2025-04-012025-06-300000927066dva:OtherSourcesofRevenueMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-04-012026-06-300000927066dva:OtherSourcesofRevenueMemberus-gaap:AllOtherSegmentsMember2026-04-012026-06-300000927066dva:OtherSourcesofRevenueMember2026-04-012026-06-300000927066dva:OtherSourcesofRevenueMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-04-012025-06-300000927066dva:OtherSourcesofRevenueMemberus-gaap:AllOtherSegmentsMember2025-04-012025-06-300000927066dva:OtherSourcesofRevenueMember2025-04-012025-06-300000927066us-gaap:IntersegmentEliminationMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-04-012026-06-300000927066us-gaap:IntersegmentEliminationMemberus-gaap:AllOtherSegmentsMember2026-04-012026-06-300000927066us-gaap:IntersegmentEliminationMember2026-04-012026-06-300000927066us-gaap:IntersegmentEliminationMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-04-012025-06-300000927066us-gaap:IntersegmentEliminationMemberus-gaap:AllOtherSegmentsMember2025-04-012025-06-300000927066us-gaap:IntersegmentEliminationMember2025-04-012025-06-300000927066dva:U.S.DialysisAndRelatedLabServicesMember2026-04-012026-06-300000927066us-gaap:AllOtherSegmentsMember2026-04-012026-06-300000927066dva:U.S.DialysisAndRelatedLabServicesMember2025-04-012025-06-300000927066us-gaap:AllOtherSegmentsMember2025-04-012025-06-300000927066dva:MedicareandMedicareAdvantageMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-01-012026-06-300000927066dva:MedicareandMedicareAdvantageMember2026-01-012026-06-300000927066dva:MedicareandMedicareAdvantageMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-01-012025-06-300000927066dva:MedicareandMedicareAdvantageMember2025-01-012025-06-300000927066dva:MedicaidandManagedMedicaidMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-01-012026-06-300000927066dva:MedicaidandManagedMedicaidMember2026-01-012026-06-300000927066dva:MedicaidandManagedMedicaidMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-01-012025-06-300000927066dva:MedicaidandManagedMedicaidMember2025-01-012025-06-300000927066dva:OtherGovernmentPayorsMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-01-012026-06-300000927066dva:OtherGovernmentPayorsMemberus-gaap:AllOtherSegmentsMember2026-01-012026-06-300000927066dva:OtherGovernmentPayorsMember2026-01-012026-06-300000927066dva:OtherGovernmentPayorsMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-01-012025-06-300000927066dva:OtherGovernmentPayorsMemberus-gaap:AllOtherSegmentsMember2025-01-012025-06-300000927066dva:OtherGovernmentPayorsMember2025-01-012025-06-300000927066dva:CommercialPayorsMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-01-012026-06-300000927066dva:CommercialPayorsMemberus-gaap:AllOtherSegmentsMember2026-01-012026-06-300000927066dva:CommercialPayorsMember2026-01-012026-06-300000927066dva:CommercialPayorsMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-01-012025-06-300000927066dva:CommercialPayorsMemberus-gaap:AllOtherSegmentsMember2025-01-012025-06-300000927066dva:CommercialPayorsMember2025-01-012025-06-300000927066dva:MedicareandMedicareAdvantageMemberus-gaap:AllOtherSegmentsMember2026-01-012026-06-300000927066dva:MedicareandMedicareAdvantageMemberus-gaap:AllOtherSegmentsMember2025-01-012025-06-300000927066dva:MedicaidandManagedMedicaidMemberus-gaap:AllOtherSegmentsMember2026-01-012026-06-300000927066dva:MedicaidandManagedMedicaidMemberus-gaap:AllOtherSegmentsMember2025-01-012025-06-300000927066dva:OtherSourcesofRevenueMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-01-012026-06-300000927066dva:OtherSourcesofRevenueMemberus-gaap:AllOtherSegmentsMember2026-01-012026-06-300000927066dva:OtherSourcesofRevenueMember2026-01-012026-06-300000927066dva:OtherSourcesofRevenueMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-01-012025-06-300000927066dva:OtherSourcesofRevenueMemberus-gaap:AllOtherSegmentsMember2025-01-012025-06-300000927066dva:OtherSourcesofRevenueMember2025-01-012025-06-300000927066us-gaap:IntersegmentEliminationMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-01-012026-06-300000927066us-gaap:IntersegmentEliminationMemberus-gaap:AllOtherSegmentsMember2026-01-012026-06-300000927066us-gaap:IntersegmentEliminationMember2026-01-012026-06-300000927066us-gaap:IntersegmentEliminationMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-01-012025-06-300000927066us-gaap:IntersegmentEliminationMemberus-gaap:AllOtherSegmentsMember2025-01-012025-06-300000927066us-gaap:IntersegmentEliminationMember2025-01-012025-06-300000927066dva:U.S.DialysisAndRelatedLabServicesMember2026-01-012026-06-300000927066us-gaap:AllOtherSegmentsMember2026-01-012026-06-300000927066dva:U.S.DialysisAndRelatedLabServicesMember2025-01-012025-06-300000927066us-gaap:AllOtherSegmentsMember2025-01-012025-06-300000927066dva:CustomerContractAssetsMember2026-06-300000927066dva:CustomerContractAssetsMember2025-12-310000927066dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember2026-06-300000927066dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember2025-12-310000927066dva:MutualFundsAndCommonStockMember2026-06-300000927066dva:MutualFundsAndCommonStockMember2025-12-310000927066us-gaap:ShortTermInvestmentsMember2026-06-300000927066us-gaap:ShortTermInvestmentsMember2025-12-310000927066us-gaap:OtherLongTermInvestmentsMember2026-06-300000927066us-gaap:OtherLongTermInvestmentsMember2025-12-310000927066dva:U.S.DialysisMember2024-12-310000927066us-gaap:AllOtherSegmentsMember2024-12-310000927066dva:U.S.DialysisMember2026-01-012026-03-310000927066us-gaap:AllOtherSegmentsMember2026-01-012026-03-3100009270662025-01-012025-03-3100009270662026-01-012026-03-310000927066dva:U.S.DialysisMember2025-12-310000927066us-gaap:AllOtherSegmentsMember2025-12-310000927066dva:U.S.DialysisMember2026-01-012026-06-300000927066dva:U.S.DialysisMember2026-06-300000927066us-gaap:AllOtherSegmentsMember2026-06-300000927066dva:OtherReportingUnitsMember2026-01-012026-06-300000927066dva:TermLoanA2Member2026-06-300000927066dva:TermLoanA2Member2025-12-310000927066dva:TermLoanA2Member2026-01-012026-06-300000927066dva:TermLoanA2AndRevolverMember2026-01-012026-06-300000927066dva:TermLoanB2Member2026-06-300000927066dva:TermLoanB2Member2025-12-310000927066dva:TermLoanB2Member2026-01-012026-06-300000927066dva:TermLoanB2Member2026-04-012026-06-300000927066us-gaap:RevolvingCreditFacilityMember2026-06-300000927066us-gaap:RevolvingCreditFacilityMember2025-12-310000927066us-gaap:RevolvingCreditFacilityMember2026-01-012026-06-300000927066dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember2026-06-300000927066dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember2025-12-310000927066dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember2026-01-012026-06-300000927066dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember2026-06-300000927066dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember2025-12-310000927066dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember2026-01-012026-06-300000927066dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember2026-06-300000927066dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember2025-12-310000927066dva:SeniorNotesSixPointEightSevenFivePercentDueTwentyThirtyTwoMember2026-01-012026-06-300000927066dva:SeniorNotesSixPointSevenFivePercentDueTwentyThirtyThreeMember2026-06-300000927066dva:SeniorNotesSixPointSevenFivePercentDueTwentyThirtyThreeMember2025-12-310000927066dva:SeniorNotesSixPointSevenFivePercentDueTwentyThirtyThreeMember2026-01-012026-06-300000927066us-gaap:NotesPayableOtherPayablesMember2026-06-300000927066us-gaap:NotesPayableOtherPayablesMember2025-12-310000927066us-gaap:NotesPayableOtherPayablesMember2026-01-012026-06-300000927066dva:FinanceLeaseMember2026-06-300000927066dva:FinanceLeaseMember2025-12-310000927066dva:FinanceLeaseMember2026-01-012026-06-300000927066dva:TermLoanA2Memberus-gaap:RevolvingCreditFacilityMember2026-04-012026-06-300000927066dva:TermLoanB2Member2026-06-082026-06-080000927066dva:TermLoanB2Member2026-06-082026-06-080000927066dva:TermLoanB2Member2026-06-080000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:A2023InterestRateCapAgreements4.50EffectiveJune302024Member2026-06-300000927066dva:A2023InterestRateCapAgreements4.50EffectiveJune302024Member2026-01-012026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member2026-06-300000927066dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member2026-01-012026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:A2024InterestRateCapAgreements4.50EffectiveDecember312025Member2026-06-300000927066dva:A2024InterestRateCapAgreements4.50EffectiveDecember312025Member2026-01-012026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:A2024InterestRateCapAgreements4.00EffectiveDecember312025Member2026-06-300000927066dva:A2024InterestRateCapAgreements4.00EffectiveDecember312025Member2026-01-012026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:A2025InterestRateCapAgreements4.50EffectiveDecember312026Member2026-06-300000927066dva:A2025InterestRateCapAgreements4.50EffectiveDecember312026Member2026-01-012026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:A2025InterestRateCapAgreements4.25EffectiveDecember312026Member2026-06-300000927066dva:A2025InterestRateCapAgreements4.25EffectiveDecember312026Member2026-01-012026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:A2025InterestRateCapAgreements4.25EffectiveDecember312027Member2026-06-300000927066dva:A2025InterestRateCapAgreements4.25EffectiveDecember312027Member2026-01-012026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:A2025InterestRateCapAgreements4.50EffectiveDecember312028Member2026-06-300000927066dva:A2025InterestRateCapAgreements4.50EffectiveDecember312028Member2026-01-012026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:A2026InterestRateCapAgreements4.75EffectiveDecember312028Member2026-06-300000927066dva:A2026InterestRateCapAgreements4.75EffectiveDecember312028Member2026-01-012026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:TotalNotionalAmountEffectiveThroughDecember312026Member2026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:TotalNotionalAmountEffectiveThroughDecember312027Member2026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:TotalNotionalAmountEffectiveThroughDecember312028Member2026-06-300000927066dva:TermLoanFacilityMembersrt:MaximumMemberdva:TotalNotionalAmountEffectiveThroughDecember312029Member2026-06-300000927066dva:TermLoanFacilityMembersrt:WeightedAverageMemberdva:TotalNotionalAmountEffectiveThroughDecember312026Member2026-06-300000927066dva:TermLoanFacilityMembersrt:WeightedAverageMemberdva:TotalNotionalAmountEffectiveThroughDecember312027Member2026-06-300000927066dva:TermLoanFacilityMembersrt:WeightedAverageMemberdva:TotalNotionalAmountEffectiveThroughDecember312028Member2026-06-300000927066dva:TermLoanFacilityMembersrt:WeightedAverageMemberdva:TotalNotionalAmountEffectiveThroughDecember312029Member2026-06-300000927066us-gaap:SubsequentEventMemberdva:TermLoanFacilityMembersrt:MaximumMemberdva:A2024InterestRateCapAgreements4.50EffectiveDecember312025Member2026-12-310000927066us-gaap:SubsequentEventMemberdva:TermLoanFacilityMembersrt:MaximumMemberdva:A2024InterestRateCapAgreements4.00EffectiveDecember312025Member2026-12-310000927066us-gaap:SubsequentEventMemberdva:TermLoanFacilityMembersrt:MaximumMemberdva:A2025InterestRateCapAgreements4.50EffectiveDecember312026Member2027-12-310000927066us-gaap:SubsequentEventMemberdva:TermLoanFacilityMembersrt:MaximumMemberdva:A2025InterestRateCapAgreements4.25EffectiveDecember312026Member2027-12-310000927066dva:SeniorSecuredCreditFacilitiesMember2026-06-300000927066us-gaap:LetterOfCreditMember2026-06-300000927066dva:BilateralSecuredLetterOfCreditFacilityMember2026-06-3000009270662019-10-222019-10-220000927066us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-06-300000927066us-gaap:StockAppreciationRightsSARSMember2026-01-012026-06-300000927066dva:OpenMarketPurchasesMember2026-04-012026-06-300000927066dva:OpenMarketPurchasesMember2026-01-012026-06-300000927066dva:BerkshireRepurchasesMember2026-04-012026-06-300000927066dva:BerkshireRepurchasesMember2026-01-012026-06-300000927066us-gaap:PrincipalOwnerMember2026-01-012026-06-300000927066us-gaap:PrincipalOwnerMember2026-04-012026-06-300000927066us-gaap:PrincipalOwnerMember2026-03-312026-03-310000927066us-gaap:PrincipalOwnerMember2026-06-300000927066us-gaap:SubsequentEventMemberus-gaap:PrincipalOwnerMember2026-07-312026-07-310000927066us-gaap:SubsequentEventMember2026-07-310000927066us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2026-03-310000927066us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2026-03-310000927066us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2026-03-310000927066us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-12-310000927066us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-12-310000927066us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-12-310000927066us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2026-04-012026-06-300000927066us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2026-04-012026-06-300000927066us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2026-04-012026-06-300000927066us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2026-01-012026-06-300000927066us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2026-01-012026-06-300000927066us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2026-01-012026-06-300000927066us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2026-06-300000927066us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2026-06-300000927066us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2026-06-300000927066us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-03-310000927066us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-03-310000927066us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-03-310000927066us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-03-310000927066us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-12-310000927066us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-12-310000927066us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-12-310000927066us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-12-310000927066us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-04-012025-06-300000927066us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-04-012025-06-300000927066us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-04-012025-06-300000927066us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-04-012025-06-300000927066us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-01-012025-06-300000927066us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-01-012025-06-300000927066us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-01-012025-06-300000927066us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-01-012025-06-300000927066us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-06-300000927066us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-06-300000927066us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-06-300000927066us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-06-300000927066us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2026-06-300000927066us-gaap:FairValueMeasurementsRecurringMember2026-06-300000927066us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-06-300000927066us-gaap:InterestRateCapMemberus-gaap:FairValueMeasurementsRecurringMember2026-06-300000927066us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel2Member2026-06-300000927066us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-06-300000927066dva:U.S.DialysisWithIntersegmentMemberdva:ExternalSourcesMemberus-gaap:OperatingSegmentsMember2026-04-012026-06-300000927066dva:U.S.DialysisWithIntersegmentMemberdva:ExternalSourcesMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000927066dva:U.S.DialysisWithIntersegmentMemberdva:ExternalSourcesMemberus-gaap:OperatingSegmentsMember2026-01-012026-06-300000927066dva:U.S.DialysisWithIntersegmentMemberdva:ExternalSourcesMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000927066dva:U.S.DialysisWithIntersegmentMemberus-gaap:IntersubsegmentEliminationsMemberus-gaap:OperatingSegmentsMember2026-04-012026-06-300000927066dva:U.S.DialysisWithIntersegmentMemberus-gaap:IntersubsegmentEliminationsMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000927066dva:U.S.DialysisWithIntersegmentMemberus-gaap:IntersubsegmentEliminationsMemberus-gaap:OperatingSegmentsMember2026-01-012026-06-300000927066dva:U.S.DialysisWithIntersegmentMemberus-gaap:IntersubsegmentEliminationsMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000927066us-gaap:OperatingSegmentsMemberdva:U.S.DialysisWithIntersegmentMember2026-04-012026-06-300000927066us-gaap:OperatingSegmentsMemberdva:U.S.DialysisWithIntersegmentMember2025-04-012025-06-300000927066us-gaap:OperatingSegmentsMemberdva:U.S.DialysisWithIntersegmentMember2026-01-012026-06-300000927066us-gaap:OperatingSegmentsMemberdva:U.S.DialysisWithIntersegmentMember2025-01-012025-06-300000927066us-gaap:OperatingSegmentsMemberdva:OtherOperatingSegmentsWithIntersegmentMember2026-04-012026-06-300000927066us-gaap:OperatingSegmentsMemberdva:OtherOperatingSegmentsWithIntersegmentMember2025-04-012025-06-300000927066us-gaap:OperatingSegmentsMemberdva:OtherOperatingSegmentsWithIntersegmentMember2026-01-012026-06-300000927066us-gaap:OperatingSegmentsMemberdva:OtherOperatingSegmentsWithIntersegmentMember2025-01-012025-06-300000927066dva:OtherOperatingSegmentsWithIntersegmentMemberus-gaap:IntersubsegmentEliminationsMemberus-gaap:OperatingSegmentsMember2026-04-012026-06-300000927066dva:OtherOperatingSegmentsWithIntersegmentMemberus-gaap:IntersubsegmentEliminationsMemberus-gaap:OperatingSegmentsMember2025-04-012025-06-300000927066dva:OtherOperatingSegmentsWithIntersegmentMemberus-gaap:IntersubsegmentEliminationsMemberus-gaap:OperatingSegmentsMember2026-01-012026-06-300000927066dva:OtherOperatingSegmentsWithIntersegmentMemberus-gaap:IntersubsegmentEliminationsMemberus-gaap:OperatingSegmentsMember2025-01-012025-06-300000927066us-gaap:OperatingSegmentsMember2026-04-012026-06-300000927066us-gaap:OperatingSegmentsMember2025-04-012025-06-300000927066us-gaap:OperatingSegmentsMember2026-01-012026-06-300000927066us-gaap:OperatingSegmentsMember2025-01-012025-06-300000927066us-gaap:OperatingSegmentsMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-04-012026-06-300000927066us-gaap:OperatingSegmentsMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-04-012025-06-300000927066us-gaap:OperatingSegmentsMemberdva:U.S.DialysisAndRelatedLabServicesMember2026-01-012026-06-300000927066us-gaap:OperatingSegmentsMemberdva:U.S.DialysisAndRelatedLabServicesMember2025-01-012025-06-300000927066us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2026-04-012026-06-300000927066us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2025-04-012025-06-300000927066us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2026-01-012026-06-300000927066us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2025-01-012025-06-300000927066us-gaap:SubsequentEventMemberdva:ElaraCaringMember2026-07-202026-07-200000927066us-gaap:SubsequentEventMemberdva:TermLoanFacilityMembersrt:MaximumMemberdva:A2026InterestRateCapAgreementsSOFREffectiveDecember292028Member2026-07-070000927066us-gaap:SubsequentEventMemberdva:TermLoanFacilityMemberdva:A2026InterestRateCapAgreementsSOFREffectiveDecember292028Member2026-07-072026-07-07



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended June 30, 2026
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
Commission File Number: 1-14106
logoa33.jpg
DAVITA INC.
Delaware51-0354549
(State of incorporation)(I.R.S. Employer Identification No.)
2000 16th Street
Denver,CO80202
Telephone number (720) 631-2100
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:Trading symbol(s):Name of each exchange on which registered:
Common Stock, $0.001 par valueDVANYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐ Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)    Yes  ☐    No  ☒
As of July 31, 2026, the number of shares of the registrant’s common stock outstanding was approximately 63.8 million shares.


DAVITA INC.
INDEX

Page No.
PART I. FINANCIAL INFORMATION
Item 1.
Consolidated Statements of Income for the three and six months ended June 30, 2026 and
 June 30, 2025
1
Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2026 and June 30, 2025
2
Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025
3
Consolidated Statements of Cash Flow for the six months ended June 30, 2026 and June 30, 2025
4
Consolidated Statements of Equity for the three and six months ended June 30, 2026 and
 June 30, 2025
5
Notes to Condensed Consolidated Financial Statements
7
Item 2.
21
Item 3.
36
Item 4.
36
PART II. OTHER INFORMATION
Item 1.
36
Item 1A.
36
Item 2.
36
Item 3.
37
Item 4.
37
Item 5.
37
Item 6.
38
39
    

i


DAVITA INC.
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(dollars and shares in thousands, except per share data)


Three months ended June 30,Six months ended June 30,
2026202520262025
Dialysis patient service revenues$3,366,377 $3,206,871 $6,639,174 $6,309,864 
Other revenues187,707 172,655 330,458 293,191 
Total revenues3,554,084 3,379,526 6,969,632 6,603,055 
Operating expenses:
Patient care costs2,392,001 2,261,540 4,734,258 4,501,200 
General and administrative423,458 412,805 845,372 786,895 
Depreciation and amortization167,808 174,704 345,637 351,155 
Equity investment income, net(8,184)(7,364)(16,528)(12,973)
Total operating expenses2,975,083 2,841,685 5,908,739 5,626,277 
Operating income579,001 537,841 1,060,893 976,778 
Debt expense(150,256)(146,062)(295,387)(281,117)
Debt extinguishment and modification costs(2,035)— (2,035)— 
Other income (loss), net8,300 (22,851)12,773 (40,400)
Income before income taxes435,010 368,928 776,244 655,261 
Income tax expense91,787 93,708 157,986 147,825 
Net income343,223 275,220 618,258 507,436 
Less: Net income attributable to noncontrolling interests(77,826)(75,883)(155,331)(145,182)
Net income attributable to DaVita Inc.$265,397 $199,337 $462,927 $362,254 
Earnings per share attributable to DaVita Inc.:
Basic net income$4.10 $2.62 $7.01 $4.67 
Diluted net income$4.02 $2.58 $6.86 $4.57 
Weighted average shares for earnings per share:
Basic shares64,781 75,943 66,078 77,646 
Diluted shares66,092 77,362 67,476 79,309 
See notes to condensed consolidated financial statements.
1

DAVITA INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited)
(dollars in thousands)
Three months ended June 30,Six months ended June 30,
2026202520262025
Net income$343,223 $275,220 $618,258 $507,436 
Other comprehensive income (loss), net of tax:
Unrealized gains (losses) on interest rate cap agreements:
Unrealized gains (losses)2,799 (6,405)7,953 (14,940)
Reclassifications of net realized losses into net income2,877 1,534 5,754 3,041 
Unrealized gains on foreign currency translation22,732 94,001 50,525 184,857 
Other comprehensive income28,408 89,130 64,232 172,958 
Total comprehensive income371,631 364,350 682,490 680,394 
Less: Comprehensive income attributable to noncontrolling interests(77,826)(75,883)(155,331)(145,182)
Comprehensive income attributable to DaVita Inc.$293,805 $288,467 $527,159 $535,212 
See notes to condensed consolidated financial statements.
2

DAVITA INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(dollars and shares in thousands, except per share data)
June 30, 2026December 31, 2025
ASSETS
Cash and cash equivalents$668,963 $676,438 
Restricted cash and equivalents82,895 81,309 
Short-term investments19,914 24,303 
Accounts receivable2,467,056 2,414,690 
Inventories151,535 160,627 
Contract assets and other receivables565,566 494,414 
Prepaid and other current assets149,113 156,285 
Income tax receivable84,597 49,937 
Total current assets4,189,639 4,058,003 
Property and equipment, net of accumulated depreciation of $6,867,296 and $6,602,134, respectively
2,749,308 2,812,966 
Operating lease right-of-use assets2,430,055 2,397,179 
Intangible assets, net of accumulated amortization of $38,030 and $37,751, respectively
228,817 222,125 
Equity method and other investments183,801 157,249 
Long-term investments38,365 40,966 
Other long-term assets298,538 246,520 
Goodwill7,590,966 7,545,095 
$17,709,489 $17,480,103 
LIABILITIES AND EQUITY
Accounts payable$715,872 $696,148 
Other liabilities826,995 893,024 
Accrued compensation and benefits694,766 793,478 
Current portion of operating lease liabilities439,488 425,484 
Current portion of long-term debt117,177 109,201 
Income tax payable24,621 24,359 
Due to related party36,513 199,940 
Total current liabilities2,855,432 3,141,634 
Long-term operating lease liabilities2,185,973 2,175,658 
Long-term debt10,663,836 10,163,988 
Other long-term liabilities99,091 83,516 
Deferred income taxes825,719 756,869 
Total liabilities16,630,051 16,321,665 
Commitments and contingencies
Noncontrolling interests subject to put provisions1,561,416 1,532,166 
Equity:
Preferred stock ($0.001 par value, 5,000 shares authorized; none issued)
— — 
Common stock ($0.001 par value, 450,000 shares authorized; 69,198 shares issued
 and 63,955 shares outstanding at June 30, 2026, 68,549 shares issued and
 outstanding at December 31, 2025)
69 69 
Additional paid-in capital— — 
Accumulated earnings (deficit)81,233 (328,428)
Treasury stock (5,243 and zero shares, respectively)
(787,847)(199,940)
Accumulated other comprehensive loss(58,551)(122,783)
Total DaVita Inc. shareholders' equity deficit(765,096)(651,082)
Noncontrolling interests not subject to put provisions283,118 277,354 
Total equity deficit(481,978)(373,728)
$17,709,489 $17,480,103 
See notes to condensed consolidated financial statements.
3

DAVITA INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(dollars in thousands)
Six months ended June 30,
20262025
Cash flows from operating activities:
Net income$618,258 $507,436 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization345,637 351,155 
Stock-based compensation expense54,189 62,567 
Deferred income taxes53,431 (9,838)
Equity investment loss, net2,437 47,730 
Other non-cash losses, net16,721 6,948 
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:
Accounts receivable(24,197)(288,447)
Inventories11,315 (9,592)
Other current assets(58,339)(70,945)
Other long-term assets(22,803)2,981 
Accounts payable7,639 35,612 
Accrued compensation and benefits(108,322)(125,365)
Other current liabilities(55,837)(3,586)
Income taxes(32,530)9,462 
Other long-term liabilities3,301 (11,873)
Net cash provided by operating activities810,900 504,245 
Cash flows from investing activities:
Additions of property and equipment(271,836)(264,349)
Acquisitions(38,540)(10,596)
Proceeds from asset and business sales4,392 22,400 
Purchase of debt investments held-to-maturity(298)(27,475)
Purchase of other debt and equity investments(12,867)(3,002)
Proceeds from debt investments held-to-maturity942 48,014 
Proceeds from sale of other debt and equity investments4,382 6,379 
Purchase of equity method investments(19,625)(2,144)
Distributions from equity method investments109 1,470 
Net cash used in investing activities(333,341)(229,303)
Cash flows from financing activities:
Borrowings2,768,259 4,189,716 
Payments on long-term debt(2,264,356)(3,373,300)
Deferred and debt related financing costs(4,645)(25,133)
Purchase of treasury stock from related party(382,805)(200,261)
Other purchases of treasury stock(377,852)(793,834)
Distributions to noncontrolling interests(149,892)(151,087)
Net proceeds from issuance of common stock under employee stock plans5,909 8,913 
Payment of tax withholdings on net share settlements of equity awards(63,814)(30,477)
Contributions from noncontrolling interests4,239 2,578 
Proceeds from sales of additional noncontrolling interests— 169 
Purchases of noncontrolling interests(18,571)(5,378)
Net cash used in financing activities(483,528)(378,094)
Effect of exchange rate changes on cash, cash equivalents and restricted cash80 20,286 
Net decrease in cash, cash equivalents and restricted cash(5,889)(82,866)
Cash, cash equivalents and restricted cash at beginning of the year757,747 879,825 
Cash, cash equivalents and restricted cash at end of the period$751,858 $796,959 
See notes to condensed consolidated financial statements.
4

DAVITA INC.
CONSOLIDATED STATEMENTS OF EQUITY
(unaudited)
(dollars and shares in thousands)
Three months ended June 30, 2026
Non-
controlling
interests
subject to
put provisions		DaVita Inc. shareholders’ equity deficitNon-
controlling
interests not
subject to
put provisions
Common stockAdditional
paid-in
capital		Accumulated (deficit) earningsTreasury stockAccumulated
other
comprehensive
loss
SharesAmountSharesAmountTotal
Balance at March 31, 2026$1,524,505 69,190 $69 $— $(179,242)(3,005)$(489,364)$(86,959)$(755,496)$279,157 
Comprehensive income:
Net income53,632 265,397 265,397 24,194 
Other comprehensive
 income		28,408 28,408 
Stock award plan8 — (658)(658)
Stock-settled stock-based
 compensation expense		23,451 23,451 
Changes in noncontrolling
 interest from:
Distributions(44,041)(20,411)
Contributions1 189 
Acquisitions and divestitures(11)
Partial purchases(116)(280)(280)
Fair value remeasurements27,435 (22,513)(4,922)(27,435)
Purchase of treasury stock(2,238)(348,470)(348,470)
Share purchase obligation49,987 49,987 
Balance at June 30, 2026$1,561,416 69,198 $69 $— $81,233 (5,243)$(787,847)$(58,551)$(765,096)$283,118 
                                                

Six months ended June 30, 2026
Non-
controlling
interests
subject to
put provisions		DaVita Inc. shareholders’ equity deficitNon-
controlling
interests not
subject to
put provisions
Common stockAdditional
paid-in
capital		Accumulated (deficit) earningsTreasury stockAccumulated
other
comprehensive
loss		Total
SharesAmountSharesAmount
Balance at December 31, 2025$1,532,166 68,549 $69 $— $(328,428)— $(199,940)$(122,783)$(651,082)$277,354 
Comprehensive income:
Net income103,770 462,927 462,927 51,561 
Other comprehensive
 income		64,232 64,232 
Stock award plan649 — (27,892)(35,921)(63,813)
Stock-settled stock-based
 compensation expense		50,057 50,057 
Changes in noncontrolling
 interest from:
Distributions(99,726)(50,166)
Contributions2,505 1,734 
Acquisitions and divestitures2,635 
Partial purchases(13,158)348 (3,999)(3,651)
Fair value remeasurements35,859 (22,513)(13,346)(35,859)
Purchase of treasury stock(5,243)(751,334)(751,334)
Share purchase obligation163,427 163,427 
Balance at June 30, 2026$1,561,416 69,198 $69 $— $81,233 (5,243)$(787,847)$(58,551)$(765,096)$283,118 


5

DAVITA INC.
CONSOLIDATED STATEMENTS OF EQUITY — (continued)
(unaudited)
(dollars and shares in thousands)
Three months ended June 30, 2025
Non-
controlling
interests
subject to
put provisions		DaVita Inc. shareholders’ equity deficitNon-
controlling
interests not
subject to
put provisions
Common stockAdditional
paid-in
capital		Retained EarningsTreasury stockAccumulated
other
comprehensive
loss
SharesAmountSharesAmountTotal
Balance at March 31, 2025$1,666,521 90,770 $91 $299,467 $1,697,547 (13,493)$(2,037,238)$(226,968)$(267,101)$260,549 
Comprehensive income:
Net income54,394 199,337 199,337 21,489 
Other comprehensive
 income		89,130 89,130 
Stock award plan7 — (312)(312)
Stock-settled stock-based
 compensation expense		32,485 32,485 
Changes in noncontrolling
 interest from:
Distributions(35,266)(22,799)
Contributions409 
Acquisitions and divestitures191 (15)(15)2,427 
Fair value remeasurements(25,259)25,259 25,259 
Purchase of treasury stock(3,067)(446,024)(446,024)
Share purchase obligation(2,392)(2,392)
Balance at June 30, 2025$1,660,990 90,777 $91 $356,884 $1,896,884 (16,560)$(2,485,654)$(137,838)$(369,633)$261,666 

Six months ended June 30, 2025
Non-
controlling
interests
subject to
put provisions		DaVita Inc. shareholders’ equity (deficit)Non-
controlling
interests not
subject to
put provisions
Common stockAdditional
paid-in
capital		Retained
earnings		Treasury stockAccumulated
other
comprehensive
loss		Total
SharesAmountSharesAmount
Balance at December 31, 2024$1,695,483 90,369 $90 $286,270 $1,534,630 (9,833)$(1,389,072)$(310,796)$121,122 $274,746 
Comprehensive income:
Net income99,624 362,254 362,254 45,558 
Other comprehensive
 income		172,958 172,958 
Stock award plan408 1 (30,477)(30,476)
Stock-settled stock-based
 compensation expense		61,854 61,854 
Changes in noncontrolling
 interest from:
Distributions(96,587)(54,500)
Contributions2,360 218 
Acquisitions and divestitures4,545 (15)(15)(4,356)
Partial purchases(5,865)682 682 
Fair value remeasurements(38,570)38,570 38,570 
Purchase of treasury stock(6,727)(996,246)(996,246)
Share purchase Obligation(100,336)(100,336)
Balance at June 30, 2025$1,660,990 90,777 $91 $356,884 $1,896,884 (16,560)$(2,485,654)$(137,838)$(369,633)$261,666 
See notes to condensed consolidated financial statements.




6

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(dollars and shares in thousands, except per share data)

Unless otherwise indicated in this Quarterly Report on Form 10-Q, "the Company", "we", "us", "our" and similar terms refer to DaVita Inc. and its consolidated subsidiaries.
1.     Condensed consolidated interim financial statements
The unaudited condensed consolidated interim financial statements included in this report are prepared by the Company. In the opinion of management, all adjustments necessary for a fair presentation of the results of operations are reflected in these condensed consolidated interim financial statements. All significant intercompany accounts and transactions have been eliminated. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies, and noncontrolling interests subject to put provisions. The most significant estimates and assumptions underlying these financial statements and accompanying notes generally involve revenue recognition and accounts receivable, certain fair value estimates, accounting for income taxes, and loss contingencies. The results of operations reflected in these interim financial statements may not necessarily be indicative of annual operating results. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (2025 10-K). Prior period classifications conform to the current period presentation.
2.     Revenue recognition
The following tables summarize the Company's segment revenues by primary payor source:
Three months ended June 30, 2026Three months ended June 30, 2025
U.S. dialysisOther — Ancillary servicesConsolidatedU.S. dialysisOther — Ancillary servicesConsolidated
Dialysis patient service revenues:
Medicare and Medicare Advantage$1,749,289 $$1,749,289 $1,659,607 $$1,659,607 
Medicaid and Managed Medicaid226,944 226,944 217,699 217,699 
Other government88,848 236,377 325,225 83,104 224,937 308,041 
Commercial940,228 136,052 1,076,280 947,015 91,225 1,038,240 
Other revenues:
Medicare and Medicare Advantage151,824 151,824 140,149 140,149 
Medicaid and Managed Medicaid— — — — 
Commercial6,241 6,241 8,322 8,322 
Other(1)
6,514 26,215 32,729 5,966 21,054 27,020 
Eliminations of intersegment revenues(11,361)(3,087)(14,448)(16,716)(2,836)(19,552)
Total$3,000,462 $553,622 $3,554,084 $2,896,675 $482,851 $3,379,526 


7

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

Six months ended June 30, 2026Six months ended June 30, 2025
U.S. dialysisOther — Ancillary servicesConsolidatedU.S. dialysisOther — Ancillary servicesConsolidated
Dialysis patient service revenues:
Medicare and Medicare Advantage$3,424,703 $$3,424,703 $3,268,625 $$3,268,625 
Medicaid and Managed Medicaid439,773 439,773 424,208 424,208 
Other government181,788 484,556 666,344 159,850 435,301 595,151 
Commercial1,894,471 245,716 2,140,187 1,871,903 178,427 2,050,330 
Other revenues:
Medicare and Medicare Advantage260,331 260,331 239,103 239,103 
Medicaid and Managed Medicaid— — 2 2 
Commercial9,889 9,889 11,023 11,023 
Other(1)
12,790 53,823 66,613 11,974 36,654 48,628 
Eliminations of intersegment revenues(31,833)(6,375)(38,208)(28,450)(5,565)(34,015)
Total$5,921,692 $1,047,940 $6,969,632 $5,708,110 $894,945 $6,603,055 
(1)    Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.
There are significant uncertainties associated with estimating revenue, many of which take several years to resolve. These estimates are subject to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor issues, as well as patient issues, including determination of applicable primary and secondary coverage, changes in patient insurance coverage and coordination of benefits. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period.
Measurements of revenue for the Company's integrated kidney care (IKC) risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met. For its IKC business, the Company recognized revenues for performance obligations satisfied in previous years of $98,491 and $95,911 during the six months ended June 30, 2026 and 2025, respectively. The delay in recognition of these amounts resulted predominantly from measurement limitations and recognition constraints on the Company's value-based care contracts with health plans, many of which are complex. Recognition of revenue from the Company's government Comprehensive Kidney Care Contracting program also has certain constraints for plan years 2025 and 2026.
Customer contract assets. The carrying value of customer contract assets, which are included in contract assets and other receivables and other long-term assets on the Company’s consolidated balance sheet, was $399,165 and $310,541 as of June 30, 2026 and December 31, 2025, respectively.
3.    Earnings per share
Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.
Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.
8

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:
Three months ended June 30,Six months ended June 30,
2026202520262025
Net income attributable to DaVita Inc.$265,397 $199,337 $462,927 $362,254 
Weighted average shares outstanding:
Basic shares64,781 75,943 66,078 77,646 
Assumed incremental from stock plans1,311 1,419 1,398 1,663 
Diluted shares66,092 77,362 67,476 79,309 
Basic net income per share attributable to DaVita Inc.$4.10 $2.62 $7.01 $4.67 
Diluted net income per share attributable to DaVita Inc.$4.02 $2.58 $6.86 $4.57 
Anti-dilutive stock-settled awards excluded from calculation(1)
102 266 247 226 
(1)Shares associated with stock plans excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.
4.     Short-term and long-term investments
The Company’s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:
June 30, 2026December 31, 2025
Debt
securities		Equity
securities		TotalDebt
securities		Equity
securities		Total
Certificates of deposit, bonds and other$16,414 $— $16,414 $24,320 $— $24,320 
Investments in mutual funds— 41,865 41,865 — 40,949 40,949 
$16,414 $41,865 $58,279 $24,320 $40,949 $65,269 
Short-term investments$16,414 $3,500 $19,914 $19,903 $4,400 $24,303 
Long-term investments— 38,365 38,365 4,417 36,549 40,966 
$16,414 $41,865 $58,279 $24,320 $40,949 $65,269 
9

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

5.     Goodwill
Changes in the carrying value of goodwill by reportable segment were as follows:
U.S. dialysisOther — Ancillary servicesConsolidated
Balance at December 31, 2024$6,517,220 $857,996 $7,375,216 
Acquisitions10,396 61,288 71,684 
Foreign currency and other adjustments— 98,195 98,195 
Balance at December 31, 20256,527,616 1,017,479 7,545,095 
Acquisitions21,928 12,680 34,608 
Foreign currency and other adjustments— 11,263 11,263 
Balance at June 30, 2026$6,549,544 $1,041,422 $7,590,966 
Balance at June 30, 2026:
Goodwill6,549,544 1,194,825 7,744,369 
Accumulated impairment charges— (153,403)(153,403)
$6,549,544 $1,041,422 $7,590,966 
The Company did not recognize any goodwill impairment charges during the six months ended June 30, 2026 and 2025.
The Company performed various annual impairment assessments during the six months ended June 30, 2026, with no impairment indicated. None of the Company's various reporting units were considered at risk of significant goodwill impairment as of June 30, 2026.
10

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

6.     Long-term debt
Long-term debt comprised the following:
As of June 30, 2026
June 30,
2026		December 31, 2025Maturity dateInterest rate
Estimated fair value(1)
Senior Secured Credit Facilities:
Term Loan A-2(2)
$1,975,000 $2,000,000 11/24/2030SOFR + 1.50%$1,970,063 
Term Loan B-22,357,910 1,868,559 5/9/2031SOFR + 1.75%$2,352,015 
Revolving line of credit(2)
65,000 — 11/24/2030SOFR + 1.50%$65,000 
Senior Notes:
4.625% Senior Notes2,750,000 2,750,000 6/1/20304.625 %$2,653,750 
3.75% Senior Notes1,500,000 1,500,000 2/15/20313.75 %$1,385,625 
6.875% Senior Notes1,000,000 1,000,000 9/1/20326.875 %$1,028,750 
6.75% Senior Notes1,000,000 1,000,000 7/15/20336.75 %$1,028,750 
Acquisition obligations and other notes payable(3)
39,463 40,904 2026-20384.67 %$39,463 
Financing lease obligations(4)
160,143 185,120 2027-20394.30 %
Total debt principal outstanding10,847,516 10,344,583 
Discount, premium and deferred financing costs(66,503)(71,394)
10,781,013 10,273,189 
Less current portion(117,177)(109,201)
$10,663,836 $10,163,988 
(1)See Note 11 for discussion of the Company's fair value estimates.
(2)Outstanding Term Loan A-2 and revolving line of credit balances are due on November 24, 2030, unless any of the 4.625% senior notes due 2030 (the 4.625% Senior Notes) remain outstanding 91 days prior to the 4.625% Senior Notes maturity date, in which case the outstanding Term Loan A-2 and revolving line of credit balances become due at that 91 day date (March 2, 2030).
(3)The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of June 30, 2026.
(4)Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.
Scheduled maturities of long-term debt at June 30, 2026 were as follows:
2026 (remainder of the year)$62,283 
2027$114,026 
2028$160,808 
2029$144,566 
2030$4,554,268 
2031$3,764,157 
Thereafter$2,047,408 
On June 8, 2026 (the Ninth Amendment Effective Date), the Company entered into the Ninth Amendment (the Ninth Amendment) to the Credit Agreement. The Ninth Amendment modified the Credit Agreement to extend an additional incremental principal amount of $500,000 on its Term Loan B-2. The Company used the net proceeds from this transaction to repay a portion of the balance outstanding on its revolving line of credit and related accrued interest and fees. The Term Loan B-2 requires quarterly principal payments that began on June 30, 2026 of 0.25% of the aggregate principal amount of the Term Loan B-2 outstanding on the Ninth Amendment Effective Date, with the balance due on May 9, 2031. As a result of the Ninth Amendment, the Company recognized debt extinguishment and modification costs of $2,035 in the second quarter of 2026 comprised of fees incurred for this transaction.
11

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

During the first six months of 2026, the Company made regularly scheduled principal payments under its senior secured credit facilities totaling $25,000 on Term Loan A-2 and $10,649 on Term Loan B-2.
As of June 30, 2026, the effective portion of the Company's interest rate cap agreements, as detailed in the table below, have the economic effect of capping the Company's maximum exposure to SOFR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Term Loan B-2 and a portion of Term Loan A-2. The remaining $832,910 outstanding principal balance of Term Loan A-2 and $65,000 balance outstanding on the revolving line of credit are subject to SOFR-based interest rate volatility. The Company's interest rate cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. The original premiums paid for the caps are amortized to debt expense on a straight-line basis over the term of each cap agreement starting from its effective date. These cap agreements do not contain credit risk-contingent features.
The following table summarizes the Company’s interest rate cap agreements outstanding as of June 30, 2026: 
Year cap agreements executedInitial notional amountSOFR maximum rateApproximate effective dateMaturity dateNotional amount effective
through December 31
2026202720282029
2023$500,000 4.50%6/30/202412/31/2026$500,000 
2023$750,000 4.00%12/31/202412/31/2026$500,000 
2024$1,750,000 
4.50%(1)
12/31/202512/31/2027$1,750,000 $1,000,000 
2024$750,000 
4.00%(2)
12/31/202512/31/2027$750,000 $500,000 
2025$1,000,000 
4.50%(3)
12/31/202612/31/2028$1,000,000 $750,000 
2025$1,000,000 
4.25%(4)
12/31/202612/31/2028$1,000,000 $1,000,000 
2025$1,750,000 4.25%12/31/202712/31/2028$1,750,000 
2025$1,000,000 4.50%12/31/202812/31/2029$1,000,000 
2026$750,000 4.75%12/31/202812/31/2029$750,000 
Total notional coverage$3,500,000 $3,500,000 $3,500,000 $1,750,000 
Weighted average strike rate4.32%4.46%4.43%4.61%
(1)Effective December 31, 2026, the maximum rate of 4.50% increases to 4.75% for these interest rate caps.
(2)Effective December 31, 2026, the maximum rate of 4.00% increases to 4.25% for these interest rate caps.
(3)Effective December 31, 2027, the maximum rate of 4.50% increases to 4.75% for these interest rate caps.
(4)Effective December 31, 2027, the maximum rate of 4.25% increases to 4.50% for these interest rate caps.
See Note 9 for further details on amounts reclassified from accumulated other comprehensive loss and recorded as debt expense (offset) related to the Company’s interest rate cap agreements for the three and six months ended June 30, 2026 and 2025. See Note 11 for discussion of the Company's fair value estimates.
As a result of the variable rate cap from the Company's 2023 interest rate cap agreements, the Company’s weighted average effective interest rate on its senior secured credit facilities at the end of the second quarter of 2026 was 5.76%, based on the current margins in effect for its senior secured credit facilities as of June 30, 2026, as detailed in the table above.
The Company’s weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, premium and deferred financing costs was 5.43% as of June 30, 2026.
As of June 30, 2026, the Company had $1,435,000 available and $65,000 drawn on its $1,500,000 revolving line of credit under its senior secured credit facilities. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding under the facility, of which there were none as of June 30, 2026. The Company also had letters of credit of approximately $188,482 outstanding under a separate bilateral secured letter of credit facility as of June 30, 2026.
7.    Commitments and contingencies
The Company operates in a highly regulated industry and is a party to, or has the potential to be a party to, various lawsuits, demands, claims, qui tam suits, governmental investigations and audits (including, without limitation, investigations
12

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of June 30, 2026 and December 31, 2025, each of the Company’s recorded accruals with respect to legal proceedings and regulatory matters were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.
The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.
Certain Governmental Inquiries and Related Proceedings
2020 U.S. Attorney New Jersey Investigation: In March 2020, the U.S. Attorney’s Office, District of New Jersey served the Company with a subpoena and a Civil Investigative Demand (CID) relating to an investigation being conducted by that office and the U.S. Attorney’s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company’s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney’s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of U.S. ex rel. Doe v. DaVita Inc. and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney’s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of U.S. ex rel. Bayne v. DaVita Inc., et al. The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. On November 8, 2023, the private party relator filed a fourth amended complaint. On November 29, 2023, the Company filed a motion to dismiss the fourth amended complaint. On April 29, 2025, the Court denied the Company’s motion to dismiss. On July 21, 2025, the Company answered the complaint. The Company disputes the allegations in the complaint and intends to defend this action accordingly.
2020 California Department of Insurance Investigation: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company’s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients’ decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.
2023 District of Columbia Office of Attorney General Investigation: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company’s communications with the AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.
2024 Federal Trade Commission Investigation: In April 2024, the Company received from the Federal Trade Commission (FTC) two CIDs in connection with an industry investigation under Section 5 of the Federal Trade Commission Act regarding the acquisition of medical director services and provision of dialysis services. The CIDs cover the period from January 1, 2016 to the present and generally seek information relating to restrictive covenants, such as non-competes, with physicians. The Company is cooperating with the government in this investigation.
13

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

* * *
Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies. Negative findings or terms and conditions that the Company might agree to accept could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.
Other Proceedings
2021 Antitrust Indictment and Putative Class Action Suit: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of U.S. v. DaVita Inc., et al. alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company’s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of In re Outpatient Medical Center Employee Antitrust Litigation in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company. On October 27, 2024, the plaintiffs filed a Third Amended Complaint, seeking to bring an action on behalf of certain groups of individuals employed by the Company between March 2008 and January 2021, to which the Company responded on December 20, 2024. On September 15, 2025, the plaintiffs filed a motion to certify the class. On June 10, 2026, the Court denied the plaintiffs’ motion for class certification. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.
Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.
* * *
Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 7, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.
8.    Shareholders' equity
Stock-based compensation
During the six months ended June 30, 2026, the Company granted 727 stock-settled restricted and performance stock units with an aggregate grant-date fair value of $116,627. Additionally, the Company granted 98 stock-settled stock appreciation rights with an aggregate grant-date fair value of $5,460.
14

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

As of June 30, 2026, the Company had $195,359 in total estimated but unrecognized stock-based compensation expense under the Company's equity compensation and employee stock purchase plans. The Company expects to recognize this expense over a weighted average remaining period of 1.4 years.
Share repurchases
The following table summarizes the Company's common stock repurchases during the three and six months ended June 30, 2026:
Three months ended June 30, 2026Six months ended June 30, 2026
Shares repurchased
Amount paid(1)
Average amount(2)
Shares repurchased
Amount paid(1)
Average amount(2)
Open market repurchases:1,018 $165,605 $161.08 2,364 $368,529 $154.71 
Berkshire repurchases:1,220 182,865 $149.84 2,879 382,805 $132.97 
Total repurchases:2,238 $348,470 $154.95 5,243 $751,334 $142.77 
(1)Includes commissions and excise tax, as applicable. The excise tax is recorded as part of the cost basis of treasury shares repurchased and, as such, is included in stockholders’ equity.
(2)Excludes commissions and excise tax.
Berkshire share repurchase agreement
Pursuant to the April 30, 2024 share repurchase agreement with Berkshire Hathaway Inc. on behalf of itself and its affiliates (collectively, Berkshire), the Company had a repurchase obligation at June 30, 2026 to purchase shares from Berkshire for $36,513 in the aggregate, recorded as a payable and classified as due to related party on the Company's consolidated balance sheet. On July 31, 2026, the Company settled the Berkshire repurchase obligation in total for 183 shares of common stock for $36,513, at an average price paid of $199.55 per share.
See Note 18 to the Company's consolidated financial statements included in the 2025 10-K for further discussion of the Company’s relationship with Berkshire and the share repurchase agreement.
Share repurchase authorizations
The Company is authorized to make share repurchases pursuant to prior Board authorizations. This authorization allows the Company to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.
As of July 31, 2026, the Company has a total of $1,372,960, excluding excise taxes, available under current authorizations for additional share repurchases. Although these share repurchase authorizations do not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.
15

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

9.     Accumulated other comprehensive loss
Three months ended June 30, 2026Six months ended June 30, 2026
Interest
rate cap
agreements		Foreign
currency
translation
adjustments		Accumulated
other
comprehensive
loss		Interest
rate cap
agreements		Foreign
currency
translation
adjustments		Accumulated
other
comprehensive
loss
Beginning balance$(14,367)$(72,592)$(86,959)$(22,398)$(100,385)$(122,783)
Unrealized gains3,729 22,732 26,461 10,596 50,525 61,121 
Related income tax(930)— (930)(2,643)— (2,643)
2,799 22,732 25,531 7,953 50,525 58,478 
Reclassification into net income3,834 — 3,834 7,667 — 7,667 
Related income tax(957)— (957)(1,913)— (1,913)
2,877 — 2,877 5,754 — 5,754 
Ending balance$(8,691)$(49,860)$(58,551)$(8,691)$(49,860)$(58,551)
Three months ended June 30, 2025Six months ended June 30, 2025
Defined benefit pension planInterest
rate cap
agreements		Foreign
currency
translation
adjustments		Accumulated
other
comprehensive
loss		Defined benefit pension planInterest
rate cap
agreements		Foreign
currency
translation
adjustments		Accumulated
other
comprehensive
loss
Beginning balance$46 $(15,585)$(211,429)$(226,968)$46 $(8,557)$(302,285)$(310,796)
Unrealized (losses) gains— (8,533)94,001 85,468 — (19,906)184,857 164,951 
Related income tax— 2,128 — 2,128 — 4,966 — 4,966 
— (6,405)94,001 87,596 — (14,940)184,857 169,917 
Reclassification into net income— 2,043 — 2,043 — 4,052 — 4,052 
Related income tax— (509)— (509)— (1,011)— (1,011)
— 1,534 — 1,534 — 3,041 — 3,041 
Ending balance$46 $(20,456)$(117,428)$(137,838)$46 $(20,456)$(117,428)$(137,838)
The interest rate cap agreement net realized losses reclassified into net income are recorded as debt expense in the corresponding consolidated statements of income. See Note 6 for further details.
10.    Variable interest entities (VIEs)
At June 30, 2026, these condensed consolidated financial statements include total assets of VIEs of $619,318 and total liabilities and noncontrolling interests of VIEs to third parties of $214,273. There have been no material changes in the nature of the Company's arrangements with VIEs or its judgments concerning them from those described in Note 22 to the Company's consolidated financial statements included in the 2025 10-K.
16

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

11.    Fair values of financial instruments
The Company measures the fair value of certain assets and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, temporary equity and commitments. The Company has also classified assets and temporary equities that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the Financial Accounting Standards Board (FASB).
The following table summarizes the Company’s assets and temporary equities measured at fair value on a recurring basis as of June 30, 2026: 
TotalQuoted prices in
active markets
for identical assets
(Level 1)		Significant other
observable inputs
(Level 2)		Significant
unobservable
inputs
(Level 3)
Assets:
Investments in equity securities$41,865 $41,865 
Interest rate cap agreements$25,035 $25,035 
Temporary equity:
Noncontrolling interests subject to put provisions$1,561,416 $1,561,416 
Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 4 for further discussion.
Interest rate cap agreements, which are classified in other long-term assets on the Company's consolidated balance sheet, are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 6 for further discussion.
The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years, and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of June 30, 2026, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately $225,000. See Notes 16 and 23 to the Company's consolidated financial statements included in the 2025 10-K for further discussion of the Company’s methodology for estimating the fair value of noncontrolling interests subject to put obligations. For a reconciliation of changes in noncontrolling interests subject to put provisions for the three and six months ended June 30, 2026, see the consolidated statements of equity.
The Company's fair value estimates for its senior secured credit facilities are based upon quoted bid and ask prices for these instruments, a level 2 input. For the Company's senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. See Note 6 for further discussion of the Company's debt.
Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, investments in debt securities, accounts payable, other accrued liabilities and lease liabilities. The balances of financial instruments other than lease liabilities are presented in these condensed consolidated financial statements at June 30, 2026 at their approximate fair values due to the short-term nature of their settlements.
17

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

12.    Segment reporting
The Company’s separate operating segments include its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its operations in each foreign jurisdiction (collectively, its ancillary services). The Company also maintains a corporate administrative support function.
The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker, its Chief Executive Officer, in making decisions about allocating resources to and assessing the financial performance of the Company’s various operating lines of business. The chief operating decision maker does not review total assets by segment to make decisions regarding resources; therefore, the total assets by segment disclosure has not been included.
Currently, the U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category. See Note 24 to the Company's consolidated financial statements included in the 2025 10-K for further description of how the Company determines and measures results for its operating segments.
18

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

The following is a summary of segment revenues, segment operating margin, and a reconciliation of segment operating margin to consolidated income before income taxes:
Three months ended June 30,Six months ended June 30,
2026202520262025
Segment revenues:
U.S. dialysis
Patient service revenues:
External sources$2,993,948 $2,890,709 $5,908,902 $5,696,136 
Intersegment revenues11,361 16,716 31,833 28,450 
U.S. dialysis patient service revenues3,005,309 2,907,425 5,940,735 5,724,586 
Other revenues
External sources6,514 5,966 12,790 11,974 
Total U.S. dialysis revenues3,011,823 2,913,391 5,953,525 5,736,560 
Other—Ancillary services
Patient service revenues372,429 316,162 730,272 613,728 
Other external sources181,193 166,689 317,668 281,217 
Intersegment revenues3,087 2,836 6,375 5,565 
Total ancillary services556,709 485,687 1,054,315 900,510 
Total net segment revenues3,568,532 3,399,078 7,007,840 6,637,070 
Elimination of intersegment revenues(14,448)(19,552)(38,208)(34,015)
Consolidated revenues$3,554,084 $3,379,526 $6,969,632 $6,603,055 
Significant segment expenses:
U.S. dialysis
Patient care costs$2,004,694 $1,928,462 $3,973,750 $3,841,890 
General and administrative330,892 312,089 650,664 594,768 
Depreciation and amortization146,461 156,782 301,631 313,681 
Other segment items(1)
(8,200)(6,786)(16,464)(12,396)
U.S. dialysis segment expenses2,473,847 2,390,547 4,909,581 4,737,943 
Segment operating margin:
U.S. dialysis537,976 522,844 1,043,944 998,617 
Other—Ancillary services(2)
57,050 56,714 62,882 53,906 
Total segment operating margin595,026 579,558 1,106,826 1,052,523 
Reconciliation of segment operating income to consolidated
 income before income taxes:
Corporate administrative support(16,025)(41,717)(45,933)(75,745)
Consolidated operating income579,001 537,841 1,060,893 976,778 
Debt expense(150,256)(146,062)(295,387)(281,117)
Debt extinguishment and modification costs(2,035)— (2,035)— 
Other income (loss), net8,300 (22,851)12,773 (40,400)
Income before income taxes$435,010 $368,928 $776,244 $655,261 
 
(1)Other segment items for the Company's U.S. dialysis segment include equity income from nonconsolidated joint ventures for all periods presented.
(2)Includes depreciation and amortization of $21,347 and $17,923 for the three months ended June 30, 2026 and 2025, respectively, and $44,006 and $37,474 for the six months ended June 30, 2026 and 2025, respectively.
19

DAVITA INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)
(unaudited)
(dollars and shares in thousands, except per share data)

Expenditures for property and equipment by reportable segment were as follows:
Six months ended June 30,
20262025
U.S. dialysis$229,523 $216,902 
Other—Ancillary services42,313 47,447 
$271,836 $264,349 
 
13.    New accounting standards
New standards not yet adopted
In November 2024, the Financial Accounting Standards Board issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures, which requires disaggregated disclosure of income statement expenses, including purchases of inventory, employee compensation, depreciation, and amortization. The amendments in this ASU are effective for fiscal years beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The amendments in this ASU may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.
In September 2025, the Financial Accounting Standards Board issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use software (Subtopic 350-40), which requires capitalization of software costs when management has authorized and committed to funding a software project and it is probable that the project will be completed and used as intended. The amendments in this ASU are effective for fiscal years beginning after December 15, 2027 and interim reporting periods within those annual reporting periods. The amendments in the ASU may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.
In May 2026, the Financial Accounting Standards Board issued ASU 2026-02, Environmental Credits and Environmental Credit Obligations (Topic 818), which requires environmental credits intended for compliance or exchange to be recognized as assets and initially measured at cost, while costs for credits intended for voluntary use are expensed as incurred. Additionally, the guidance establishes impairment assessment models based on intended use and requires environmental credit obligation liabilities to be recognized based on the credits needed to settle the obligation. The amendments in this ASU are effective for fiscal years beginning after December 15, 2027 and interim reporting periods within those annual reporting periods. The amendments in this ASU must be applied using a modified retrospective approach, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.
14.    Subsequent events
Elara Caring
On February 2, 2026, the Company signed a definitive agreement to acquire a noncontrolling minority interest in Elara Caring, a leading national provider of skilled home health, hospice, behavioral health, and personal care services, which closed effective July 20, 2026. At the closing, the Company made a cash payment of $200,000, subject to certain customary post-closing adjustments.
Forward Interest Rate Cap Agreements
On July 7, 2026, the Company entered into several forward interest rate cap agreements with an aggregate notional amount of $750,000 that have the economic effect of capping the Company's exposure to Secured Overnight Financing Rate (SOFR) variable interest rate changes on specific portions of the Company's floating rate debt. These cap agreements are designated as cash flow hedges and, as a result, changes in their fair values will be reported in other comprehensive income. These cap agreements do not contain credit-risk contingent features, and become effective on December 29, 2028 and expire on December 31, 2029.
20

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-looking statements
This Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains statements that are forward-looking statements within the meaning of the federal securities laws and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. These forward-looking statements could include, among other things, statements about our balance sheet and liquidity, our expenses, revenues, billings and collections, patient census, the impact of the cybersecurity incident experienced by the Company in 2025 (cyber incident), the impact of federal government policy changes or shutdowns on our business, including with respect to federal funding and reimbursement rates of Medicare, Medicare Advantage (MA), Medicaid and other government programs, availability or cost of supplies, including without limitation the impact of evolving trade policies and tariffs and any reduction in clinical and other supplies due to any disruptions experienced by third party vendors, including with respect to our ability to provide home dialysis services, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, including potential impacts to such mix as a result of U.S. administration policies, current macroeconomic, marketplace and labor market conditions, and overall impact on our patients and teammates, as well as other statements regarding our future operations, financial condition and prospects, capital allocation plans, expenses, cost saving initiatives, other strategic initiatives, use of contract labor, government and commercial payment rates, expectations related to value-based care (VBC), integrated kidney care (IKC), MA plan enrollment and our international operations, expectations regarding increased competition and marketplace changes, including those related to new or potential entrants in the dialysis and pre-dialysis marketplace and the potential impact of innovative technologies, drugs, or other treatments on the dialysis industry, and expectations regarding our share repurchase program. All statements in this report, other than statements of historical fact, are forward-looking statements. Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "plan," "anticipate," "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on DaVita's current expectations and are based solely on information available as of the date of this report. DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things:
•external conditions, including those related to general economic, political and global health conditions, including without limitation, the impact of global events and political or governmental volatility, including in the Middle East; the impact of the domestic political environment and related developments on the current healthcare marketplace, our patients and on our business; the impact of infectious diseases or other adverse conditions on our financial condition, the chronic kidney disease population and our patient population; supply chain challenges and disruptions, including without limitation with respect to certain key services, critical clinical supplies and equipment we obtain from third parties, and including any impacts on our supply chain and cost of supplies as a result of global events, natural disasters or evolving trade policies, including tariffs; the impact on our patients and industry of continued increased competition from dialysis providers and others, including new or potential entrants in the dialysis and pre-dialysis marketplace; the impact of new or innovative technologies, drugs, or other treatments, including our ability to successfully implement new technologies, treatments or therapies in our business such as those related to middle molecule toxin clearance; elevated teammate turnover or labor costs; and our ability to respond to challenging U.S. and global economic and marketplace conditions, including, among other things, our ability to successfully identify cost saving opportunities;
•the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; our ability to negotiate and maintain contracts with these payors on competitive terms or at all; a reduction in the number or percentage of our patients under commercial plans, including, without limitation, as a result of healthcare, immigration or other policies implemented by the U.S. administration, continuing legislative efforts to restrict or prohibit the use and/or availability of charitable premium assistance, or as a result of payors implementing restrictive plan designs or resulting from negotiations with large commercial payors that we have in the past, and currently are, conducting on a concurrent basis;
•risks arising from laws, regulations or requirements applicable to us or changes thereto, including, without limitation, OBBBA and those related to trade policy, healthcare, privacy, antitrust matters, and acquisition, merger, joint venture or similar transactions and/or labor matters, and potential impacts of changes in interpretation or enforcement thereof or related litigation impacting, among other things, coverage or reimbursement rates for our services or the number of patients enrolled in or that select higher-paying commercial plans, and the risk that we make incorrect assumptions about how our patients will respond to any such developments;
21

•our ability to successfully implement our strategies with respect to IKC and VBC initiatives that may be impacted by, among other things, changes to the Comprehensive Kidney Care Contracting model and home based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment;
•a reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid or other government-based programs and the impact of the MA benchmark structure and adjustment methodologies;
•our reliance on significant suppliers, service providers and other third party vendors to provide key support to our business operations and enable our provision of services to patients, including, among others, suppliers of certain pharmaceuticals, administrative or other services or critical clinical products; and risks resulting from a closure, reduction, disruption or transition in the services or products provided to us by such suppliers, service providers and third party vendors, which may, among other things, increase our costs or expenses;
•our ability to successfully maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely and our ability to successfully adopt or adapt to new technologies, treatments or therapies, including technologies that utilize artificial intelligence;
•legal and compliance risks, such as compliance with complex, and at times, evolving government regulations and requirements, and with additional laws that may apply to our operations as we expand geographically or enter into new lines of business;
•noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party, such as the cyber incident, including, among other things, any such non-compliance or breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;
•our ability to attract, retain and motivate teammates, including key leadership personnel, our ability to manage potential disruptions to our business and operations, including potential work stoppages, and our ability to manage operating cost increases or productivity decreases that may be related to political unrest, legislative or other changes, union organizing activities, or volatility and uncertainty in the current challenging and highly competitive labor market that has experienced an ongoing nationwide shortage of skilled clinical personnel, among other things;
•changes in practice patterns, pricing, or reimbursement and payment policies or processes related to pharmaceuticals, medical equipment or supplies, including with respect to oral phosphate binders, among other things;
•our ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives that, among other things, may erode our patient base and impact reimbursement rates;
•our ability to complete and successfully integrate and operate acquisitions, mergers, dispositions, joint ventures or other strategic transactions on terms favorable to us or at all; and our ability to continue to successfully expand our operations and services in markets outside the United States, or to businesses or products outside of dialysis services;
•the variability of our cash flows, including, without limitation, any extended billing or collections cycles that may be due to, among other things, defects or operational issues in our billing systems such as those experienced during the cyber incident, or defects or operational issues in the billing systems or services of third parties on which we rely; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs;
•the effects on us or others of natural or other disasters, public health crises or severe adverse weather events such as hurricanes, earthquakes, fires or flooding;
•factors that may impact our ability to repurchase stock under our share repurchase program and the timing of any such stock repurchases, as well as any use by us of a considerable amount of available funds to repurchase stock;
•our goals and disclosures related to sustainability matters, including, among other things, evolving regulatory requirements affecting environmental, social and governance standards, measurements and reporting requirements; and
•the other risk factors, trends and uncertainties set forth in our Annual Report on Form 10-K for the year ended December 31, 2025 (2025 10-K) and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and the risks and uncertainties discussed in any subsequent reports that we file or furnish with the Securities and Exchange Commission (SEC) from time to time.
The following should be read in conjunction with our condensed consolidated financial statements.
22


Company Overview
Our principal business is to provide dialysis and related lab services to patients in the United States, which we refer to as our U.S. dialysis business. We also operate our U.S. integrated kidney care (IKC) business, our U.S. other ancillary services, and our international operations, which we collectively refer to as our ancillary services, as well as our corporate administrative support functions. Our U.S. dialysis business is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD) or end stage kidney disease (ESKD).
We assess our revenue and operating performance for our U.S. dialysis business based upon several principal metrics including, among others, treatment volume, revenue per treatment and patient care costs. Each of these metrics may be impacted by a number of factors that change from period to period and over time. For example, treatment volumes may be impacted by, among other things, mortality levels, missed treatment rates and admission rates. Revenue per treatment may be impacted by, among other things, rate changes, mix of patients with commercial plans and government programs as primary payor, timing of collections and seasonal factors such as patients meeting health plan co-insurance and deductibles. Patient care costs may be impacted by, among other things, labor market conditions and cost trends in pharmaceuticals and other medical supplies. We have set forth a discussion of certain of such factors below, and we believe that information related to changes in these metrics from period to period allows investors to assess the performance of the business.
We continue to be impacted by external conditions, including, but not limited to, those related to general economic, political and global health conditions and changing population or demographic trends. These conditions can impact our business in a variety of ways, including, among other things, by affecting our patient census, treatment volumes, revenues, results of operations and operating and other costs. Certain of these impacts could be further intensified by global events such as the ongoing conflicts in the Middle East and Ukraine that have continued to drive sociopolitical, geopolitical and economic uncertainty; severe weather events and other natural disasters; and the impact of healthcare, immigration, trade and other policies implemented by federal, state and local governments. These conditions are generally outside of our control, cannot reasonably be predicted and are interrelated or have interdependent complex consequences. As a result, the ultimate impact of these conditions on our business over time will depend on a myriad of future developments and is highly uncertain and difficult to predict. For additional discussion of general economic, marketplace and global health conditions that could impact our business, see Part I Item 1. "Business" and Part I Item 1A. "Risk Factors" in our 2025 10-K.
In the second quarter of 2026, treatment per day volumes increased compared to the second quarter of 2025. Total treatment volumes in the second quarter were slightly ahead of expectations due to, among other things, better than expected patient census that was primarily driven by lower than expected mortality partially offset by lower than expected incoming patient transfers and higher than expected missed treatments. Mortality levels over time may be influenced by a number of factors, among other things, the impact of infectious diseases on our patient population and the availability and use of vaccines, treatments and therapies. For example, emerging treatments in the United States that clear middle molecules from the blood may, among other things, reduce mortality as compared to standard dialysis treatments. Two current treatment pathways that provide middle molecule clearance are expanded hemodialysis (“expanded HD”) and hemodiafiltration (“HDF”). We will work to expand patient access to these therapies, as may be prescribed by their physician. We expect to begin offering expanded HD broadly across our network in the coming quarters.
By contrast, any adverse changes in these mortality rates, particularly in the ESKD and CKD populations, may in turn impact admission rates, treatment volumes, future revenues and non-acquired growth, among other things, and the magnitude of these cumulative impacts could have a material adverse impact on our results of operations, financial condition and cash flows. For additional detail on these risks, see the discussion in Part I Item 1A. "Risk Factors" of our 2025 10-K. For additional detail on middle molecule treatments, see the discussion in Part I Item 1. “Business” of our 2025 10-K.
Global economic conditions and political and regulatory developments, including, among other things, ongoing inflationary pressures and U.S., state and local administration policies and actions have increased, and may continue to increase, our expenses and may have an impact on our revenue per treatment. For example, the decision to let enhanced premium tax credits expire at the end of 2025 has had an adverse impact on enrollment in the Affordable Care Act exchanges and our commercial mix, which in turn adversely impacts our revenue per treatment, among other things. These global economic conditions and political and regulatory developments also continue to exert pressure on our staffing and labor costs, which have increased year over year due to, among other factors, the continuation of inflationary conditions. While the cumulative impact of any increased staffing, labor, and supply costs and other expenses could be material, we have experienced productivity improvements and we expect these efficiencies to continue throughout the year. Our industry has also experienced increased union organizing activities. For example, union petitions have been filed at a number of our clinics in California. We have had different results with elections and are in different stages with elections and legal challenges. For additional details on the risks
23

related to rising labor costs and union organizing activities, see the discussion in Part I Item 1A. "Risk Factors" of our 2025 10-K under the headings, "Our business is labor intensive..." and "Global health conditions, changing population or demographic trends, severe weather events or natural disasters and general economic and political conditions..."
We believe that the aforementioned developments and general economic, political and global health conditions will continue to impact the Company in the future. Their ultimate impact depends on future developments that are highly uncertain and difficult to predict.
Financial Results
The discussion below includes analysis of our financial condition and results of operations for the three months ended June 30, 2026 compared to the three months ended March 31, 2026, and the year-to-date periods for the six months ended June 30, 2026 compared to the six months ended June 30, 2025.
Consolidated results of operations
The following tables summarize our revenues, operating income (loss) and adjusted operating income (loss) by line of business. See the discussion of our results for each line of business following the tables. When multiple drivers are identified in the following discussion of results, they are listed in order of magnitude:
Three months endedQ2 2026 vs. Q1 2026
June 30,
2026		March 31,
2026		AmountPercent
(dollars in millions)
Revenues:
U.S. dialysis$3,012 $2,942 $70 2.4 %
Other — Ancillary services557 498 59 11.8 %
Elimination of intersegment revenues(14)(24)10 41.7 %
Total consolidated revenues$3,554 $3,416 $138 4.0 %
Operating income (loss):
U.S. dialysis$538 $506 $32 6.3 %
Other — Ancillary services57 6 51 850.0 %
Corporate administrative support(16)(30)14 46.7 %
Operating income$579 $482 $97 20.1 %
Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.
24

Six months endedYTD Q2 2026 vs. YTD Q2 2025
June 30,
2026		June 30,
2025		AmountPercent
(dollars in millions)
Revenues:
U.S. dialysis$5,954 $5,737 $217 3.8 %
Other — Ancillary services1,054 901 153 17.0 %
Elimination of intersegment revenues(38)(34)(4)(11.8)%
Total consolidated revenues$6,970 $6,603 $367 5.6 %
Operating income (loss):
U.S. dialysis$1,044 $999 $45 4.5 %
Other — Ancillary services63 54 9 16.7 %
Corporate administrative support(46)(76)30 39.5 %
Operating income$1,061 $977 $84 8.6 %
Adjusted operating income (loss)(1):
U.S. dialysis$1,044 $1,012 $32 3.2 %
Other — Ancillary services63 54 9 16.7 %
Corporate administrative support(46)(76)30 39.5 %
Adjusted operating income$1,061 $990 $71 7.2 %
Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.
(1)For a reconciliation of adjusted operating income (loss) by reportable segment, see the "Reconciliations of Non-GAAP measures" section below.
U.S. dialysis results of operations
Treatment volume:
Three months endedQ2 2026 vs. Q1 2026
June 30,
2026		March 31,
2026		AmountPercent
Dialysis treatments7,226,600 7,029,525 197,075 2.8 %
Treatment days78.0 76.7 1.3 1.7 %
Average treatments per day92,649 91,650 999 1.1 %
Number of normalized treatment days(1)
78.0 76.5 1.5 2.0 %
Average treatments per normalized day92,649 91,889 760 0.8 %
Normalized non-acquired treatment growth(2)
0.3 %0.1 %
Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.
(1)Normalized treatment days reflect treatment days adjusted to normalize for the mix of days of the week in a given period.
(2)Normalized non-acquired treatment growth reflects year over year growth in treatment volume, adjusted to exclude acquisitions and other similar transactions, and further adjusted to normalize for the number and mix of treatment days in a given quarter versus the prior year quarter.
25

Six months endedYTD Q2 2026 vs. YTD Q2 2025
June 30,
2026		June 30,
2025		AmountPercent
Dialysis treatments14,256,125 14,226,736 29,389 0.2 %
Treatment days154.7 154.7 — — %
Average treatments per day92,153 91,963 190 0.2 %
Number of normalized treatment days(1)
154.5 154.9 (0.4)(0.3)%
Average treatments per normalized day92,273 91,845 428 0.5 %
Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.
(1)Normalized treatment days reflect treatment days adjusted to normalize for the mix of days of the week in a given quarter.
Our U.S. dialysis operating revenues and expenses are directly driven by treatment volume. The increase in our U.S. dialysis treatments for the second quarter of 2026 from the first quarter of 2026 was primarily driven by an increase in treatment days and increased patient count. The increase in our U.S. dialysis treatments for the six months ended June 30, 2026 from the six months ended June 30, 2025 was primarily driven by an increase in patient count.
Revenues:
Three months endedQ2 2026 vs. Q1 2026
June 30,
2026		March 31,
2026		AmountPercent
(dollars in millions, except per treatment data)
Total revenues$3,012 $2,942 $70 2.4 %
Average patient service revenue per treatment$415.87 $417.59 $(1.72)(0.4)%
Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.
Six months endedYTD Q2 2026 vs. YTD Q2 2025
June 30,
2026		June 30,
2025		AmountPercent
(dollars in millions, except per treatment data)
Total revenues$5,954 $5,737 $217 3.8 %
Average patient service revenue per treatment$416.71 $402.38 $14.33 3.6 %
Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.
U.S. dialysis average patient service revenue per treatment for the second quarter of 2026 compared to the first quarter of 2026 decreased driven by changes in payor mix and other normal fluctuations, partially offset by seasonal improvements including patients meeting their co-insurance and deductibles, and an increase in average rates.
U.S. dialysis average patient service revenue per treatment for the six months ended June 30, 2026 increased compared to the six months ended June 30, 2025 primarily driven by Medicare base rate and other annual rate increases, as well as other normal fluctuations, partially offset by changes in payor mix.
26

In June 2026, Centers for Medicare & Medicaid Services (CMS) issued a proposed rule to update the Medicare ESRD Prospective Payment System (PPS) rate and policies for calendar year 2027. CMS estimates that the overall impact of the proposed rule will increase ESRD freestanding facilities’ average reimbursement by 1.1% in 2027 which includes a proposed increase to account for the incorporation of phosphate binders into the ESRD PPS base rate.
Operating expenses and charges:
Three months endedQ2 2026 vs. Q1 2026
June 30,
2026		March 31,
2026		AmountPercent
(dollars in millions, except per treatment data)
Patient care costs$2,005 $1,969 $36 1.8 %
General and administrative331 320 11 3.4 %
Depreciation and amortization146 155 (9)(5.8)%
Equity investment income(8)(8)— — %
Total operating expenses and charges$2,474 $2,436 $38 1.6 %
Patient care costs per treatment$277.40 $280.11 $(2.71)(1.0)%
Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.
Six months endedYTD Q2 2026 vs. YTD Q2 2025
June 30,
2026		June 30,
2025		AmountPercent
(dollars in millions, except per treatment data)
Patient care costs$3,974 $3,842 $132 3.4 %
General and administrative651 595 56 9.4 %
Depreciation and amortization302 314 (12)(3.8)%
Equity investment income(16)(12)(4)(33.3)%
Total operating expenses and charges$4,910 $4,738 $172 3.6 %
Patient care costs per treatment$278.74 $270.05 $8.69 3.2 %
Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.
Charges impacting operating income - Cybersecurity incident-related charges. During the second quarter of 2025, we experienced a cybersecurity incident that impacted certain elements of our network and resulted in a temporary disruption of our operations. As a result of our efforts to remediate the incident and restore systems with the assistance of third-party cybersecurity professionals, we incurred significant costs, including, but not limited to patient care charges of approximately $1.0 million and general and administrative expenses of approximately $12.5 million during the three and six months ended June 30, 2025. These costs did not include the impact related to business interruption on our results.
Patient care costs. U.S. dialysis patient care costs per treatment for the second quarter of 2026 decreased from the first quarter of 2026 primarily due to decreased labor costs, stemming from a seasonal decrease in payroll taxes and increased productivity levels at our dialysis centers, as well as decreased pharmaceutical costs, including phosphate binders. Additionally, our fixed other direct operating expenses positively impacted patient care costs per treatment due to increased treatments in the
second quarter of 2026. These decreases were partially offset by increases in health benefits expense.
U.S. dialysis patient care costs per treatment for the six months ended June 30, 2026 increased from the six months ended June 30, 2025 primarily due to increased compensation expenses, including increased wage rates, as well as increases in insurance costs and health benefits expense.
General and administrative expenses. U.S. dialysis general and administrative expenses in the second quarter of 2026 increased from the first quarter of 2026 primarily due to increased professional fees.
U.S. dialysis general and administrative expenses for the six months ended June 30, 2026 increased from the six months ended June 30, 2025 due to increases in IT-related costs and compensation expenses, including increased wage rates, partially offset by costs related to the cybersecurity incident, as described above.
Depreciation and amortization. U.S. dialysis depreciation and amortization expenses in the second quarter of 2026 decreased compared to the first quarter of 2026 primarily due to lower depreciation expense in the second quarter for certain leasehold improvements and fully depreciated assets.
27

U.S. dialysis depreciation and amortization expenses for the six months ended June 30, 2026 compared to the six months ended June 30, 2025 decreased primarily due to fully depreciated assets.
Equity investment income. U.S. dialysis equity investment income for the second quarter of 2026 was flat compared to the first quarter of 2026. Equity investment income for the six months ended June 30, 2026 increased compared to the six months ended June 30, 2025 due to increased profitability at certain nonconsolidated dialysis partnerships.
Operating income:
Three months endedQ2 2026 vs. Q1 2026
June 30,
2026		March 31,
2026		AmountPercent
(dollars in millions)
Operating income$538 $506 $32 6.3 %

Six months endedYTD Q2 2026 vs. YTD Q2 2025
June 30,
2026		June 30,
2025		AmountPercent
(dollars in millions)
Operating income$1,044 $999 $45 4.5 %
Adjusted operating income(1)
$1,044 $1,012 $32 3.2 %
(1)For a reconciliation of adjusted operating income by reportable segment, see the "Reconciliations of Non-GAAP measures" section below.
U.S. dialysis operating income for the second quarter of 2026 increased compared to the first quarter of 2025 as a result of all factors discussed above.
For the six months ended June 30, 2026, U.S. dialysis operating income and adjusted operating income both increased compared to the six months ended June 30, 2025, due to the factors discussed above. Operating income was impacted by the cybersecurity incident-related charges in the second quarter of 2025, as described above.
28

Other—Ancillary services
Our other operations include ancillary services that are primarily aligned with our core business of providing dialysis services to our network of patients. As of June 30, 2026, these consisted principally of our U.S. IKC business, certain U.S. other ancillary businesses (including our clinical research programs, transplant software business, and venture investment group), and our international operations.
As of June 30, 2026, DaVita IKC provided integrated care and disease management services to approximately 64,900 patients in risk-based integrated care arrangements and to an additional 5,700 patients in other integrated care arrangements. We also expect to add additional service offerings to our business and pursue additional strategic initiatives in the future as circumstances warrant, which could include, among other things, healthcare services not related to kidney disease.
For a discussion of the risks related to IKC and our ancillary services, see the discussion in the risk factors in Part I Item 1A. "Risk Factors" of our 2025 10-K under the heading, "We invest in strategic and operational initiatives to maintain our business and expand our capabilities in a complex, evolving and highly regulated environment..."
As of June 30, 2026, our international dialysis business owned or operated 595 outpatient dialysis centers located in 14 countries outside of the United States.
Ancillary services results of operations
Three months endedQ2 2026 vs. Q1 2026
June 30,
2026		March 31,
2026		AmountPercent
(dollars in millions)
Revenues:
U.S. IKC$162 $116 $46 39.7 %
U.S. other ancillary9 10 (1)(10.0)%
International386 372 14 3.8 %
Total ancillary services revenues$557 $498 $59 11.8 %
Operating income (loss)
U.S. IKC$40 $(19)$59 310.5 %
U.S. other ancillary(8)(6)(2)(33.3)%
International25 30 (5)(16.7)%
Total ancillary services operating income$57 $6 $51 850.0 %
Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.
Six months endedYTD Q2 2026 vs. YTD Q2 2025
June 30,
2026		June 30,
2025		AmountPercent
(dollars in millions)
Revenues:
U.S. IKC$278 $258 $20 7.8 %
U.S. other ancillary19 16 3 18.8 %
International758 627 131 20.9 %
Total ancillary services revenues$1,054 $901 $153 17.0 %
Operating income (loss):
U.S. IKC$21 $(3)$24 800.0 %
U.S. other ancillary(13)(10)(3)(30.0)%
International55 67 (12)(17.9)%
Total ancillary services operating income$63 $54 $9 16.7 %
Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.
29

Operating income (loss) and adjusted operating income (loss)
IKC operating income for the second quarter of 2026 compared to operating loss for the first quarter of 2026 was primarily driven by a net increase in shared savings. IKC operating income for the six months ended June 30, 2026 compared to operating loss for the six months ended June 30, 2025 was impacted by a net increase in shared savings, partially offset by decreased revenues from our special needs plans.
U.S. other ancillary services operating loss for the second quarter of 2026 remained relatively flat compared to the first quarter of 2026. U.S. other ancillary services operating loss for the six months ended June 30, 2026 increased compared to the six months ended June 30, 2025 primarily due to a reduction of the earn-out obligations related to our transplant software business in the first quarter of 2025.
International operating income for the second quarter of 2026 decreased compared to the first quarter of 2026, primarily driven by a loss on sale of divested centers. International operating income for the six months ended June 30, 2026 decreased compared to the six months ended June 30, 2025, primarily due to favorable changes in the fair value of contingent consideration associated with a prior acquisition recognized in the second quarter of 2025 and increased compensation expense.
Corporate administrative support
Three months endedQ2 2026 vs. Q1 2026
June 30,
2026		March 31,
2026		AmountPercent
(dollars in millions)
Corporate administrative support$(16)$(30)$14 46.7 %
Six months endedYTD Q2 2026 vs. YTD Q2 2025
June 30,
2026		June 30,
2025		AmountPercent
(dollars in millions)
Corporate administrative support$(46)$(76)$30 39.5 %
Corporate administrative support expenses for the second quarter of 2026 compared to the first quarter of 2026 decreased primarily due to decreased professional fees. Corporate administrative support expenses for the six months ended June 30, 2026 compared to the six months ended June 30, 2025 decreased primarily due to decreased professional fees and long-term incentive compensation.
Corporate-level charges
Three months endedQ2 2026 vs. Q1 2026
June 30,
2026		March 31,
2026		AmountPercent
(dollars in millions)
Debt expense$150 $145 $5 3.4 %
Debt extinguishment and modification costs$2 $— $2 100.0 %
Weighted average effective interest rate(1)
5.43 %5.44 %(0.01)%
Other income, net$8 $4 $4 100.0 %
Effective income tax rate21.1 %19.4 %1.7 %
Effective income tax rate attributable to DaVita Inc.(2)
25.6 %25.1 %0.5 %
Net income attributable to noncontrolling interests$78 $78 $— — %
(1)Represents our overall weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, premium and deferred financing charges as of the dates presented.
(2)For a reconciliation of our effective income tax rate attributable to DaVita Inc., see the "Reconciliations of Non-GAAP measures" section below.
30

Six months endedYTD Q2 2026 vs. YTD Q2 2025
June 30,
2026		June 30,
2025		AmountPercent
(dollars in millions)
Debt expense$295 $281 $14 5.0 %
Debt extinguishment and modification costs$2 $— $2 100.0 %
Weighted average effective interest rate(1)
5.43 %5.73 %(0.30)%
Other income (loss), net$13 $(40)$53 132.5 %
Effective income tax rate20.4 %22.6 %(2.2)%
Effective income tax rate attributable to DaVita Inc.(2)
25.4 %28.9 %(3.5)%
Net income attributable to noncontrolling interests$155 $145 $10 6.9 %
(1)Represents our overall weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, premium and deferred financing charges as of the dates presented.
(2)For a reconciliation of our effective income tax rate attributable to DaVita Inc., see the "Reconciliations of Non-GAAP measures" section below.
Debt expense
Debt expense for the second quarter of 2026 compared to the first quarter of 2026 increased primarily due to increased borrowing activity on our revolving line of credit and the issuance of Term Loan B-2 incremental amounts. Debt expense for the six months ended June 30, 2026 compared to the six months ended June 30, 2025 increased primarily due to an increase in our long-term debt balance related to the issuance of the 6.75% senior notes due 2033 in the second quarter of 2025, partially offset by decreased weighted average effective interest rates.
Debt extinguishment and modification costs
The three and six months ended June 30, 2026 included debt extinguishment and modification costs of $2 million composed of fees incurred in connection with the Term Loan B-2 incremental transaction.
Other income (loss), net
Other income for the second quarter of 2026 increased compared to the first quarter of 2026, primarily due to decreased net losses on investments. Other income for the six months ended June 30, 2026 compared to other loss for the six months ended June 30, 2025 was impacted by equity investment losses at Mozarc Medical Holding LLC recognized in 2025 and net gains on other investments in 2026 compared to net losses in 2025.
Provision for income taxes
The effective income tax rate and the effective income tax rate attributable to DaVita Inc. increased for the second quarter of 2026 compared to the first quarter of 2026 primarily due to benefits recognized in the first quarter of 2026 from stock-based compensation, partially offset by tax benefits related to renewable energy credits purchased in the second quarter of 2026.
The effective income tax rate and the effective income tax rate attributable to DaVita Inc. for the six months ended June 30, 2026 decreased compared to the six months ended June 30, 2025 primarily due to the recognition of the write down of a 2014 tax refund claim in the second quarter of 2025.
Net income attributable to noncontrolling interests
The net income attributable to noncontrolling interests for the second quarter of 2026 was relatively flat compared to the first quarter of 2026. The increase in net income attributable to noncontrolling interests for the six months ended June 30, 2026 from the six months ended June 30, 2025 was due to increased profitability at certain U.S. dialysis partnerships.
U.S. dialysis accounts receivable
Our U.S. dialysis accounts receivable balances at June 30, 2026 and December 31, 2025 were $1.719 billion and $1.610 billion, respectively, representing approximately 52 days and 49 days of revenue outstanding (DSO), respectively. The increase in DSO is primarily due to timing of collections. Our DSO calculation is based on the current quarter’s average revenues per
31

day. There were no significant changes from the first quarter of 2026 to the second quarter of 2026 in the carrying value of accounts receivable outstanding over one year old.
Liquidity and capital resources
The following table summarizes our major sources and uses of cash, cash equivalents and restricted cash:
Six months ended June 30,YTD Q2 2026 vs. YTD Q2 2025
20262025AmountPercent
(dollars in millions and shares in thousands)
Net cash provided by operating activities:
Net income$618 $507 $111 21.9 %
Non-cash items in net income472 459 13 2.8 %
Other working capital changes(260)(453)193 42.6 %
Other(20)(9)(11)(122.2)%
$811 $504 $307 60.9 %
Net cash used in investing activities:
Maintenance capital expenditures(1)
$(197)$(185)$(12)(6.5)%
Development capital expenditures(2)
(75)(80)5 6.3 %
Acquisition expenditures(39)(11)(28)(254.5)%
Proceeds from sale of self-developed properties2 21 (19)(90.5)%
Other(25)25 (50)(200.0)%
$(333)$(229)$(104)(45.4)%
Net cash used in financing activities:
Debt issuances, net$504 $815 $(311)(38.2)%
Deferred and debt-related financing costs(5)(25)20 80.0 %
Distributions to noncontrolling interests(150)(151)1 0.7 %
Contributions from noncontrolling interests4 3 1 33.3 %
Stock award exercises and other share issuances(58)(22)(36)(163.6)%
Share repurchases(761)(994)233 23.4 %
Other(19)(4)(15)(375.0)%
$(484)$(378)$(106)(28.0)%
Total number of shares repurchased5,243 6,727 (1,484)(22.1)%
Free cash flow(3)
$396 $112 $284 253.6 %
Certain columns or rows may not sum due to the presentation of rounded numbers.
(1)Maintenance capital expenditures represent capital expenditures to maintain the productive capacity of the business and include those made for investments in information technology, dialysis center renovations, capital asset replacements, and any other capital expenditures that are not development or acquisition expenditures.
(2)Development capital expenditures principally represent capital expenditures (other than acquisition expenditures) made to expand the productive capacity of the business and include those for new U.S. and international dialysis center developments, dialysis center expansions and relocations, and new or expanded contracted hospital operations.
(3)For a reconciliation of our free cash flow, see the "Reconciliations of Non-GAAP measures" section below.
Consolidated cash flows
Consolidated cash flows from operating activities during the six months ended June 30, 2026 increased compared to the six months ended June 30, 2025. The increase was principally due to an increase in operating results combined with favorable changes in working capital, benefiting from favorable collections during the six months ended June 30, 2026 compared to the disruption in collections related to the cybersecurity incident, as discussed above, during the six months ended June 30, 2025.
32

Free cash flow during the six months ended June 30, 2026 increased as compared to the six months ended June 30, 2025 primarily due to an increase in net cash provided by operating activities, as described above, partially offset by a decrease in proceeds from sale of self-developed properties.
Significant sources of cash during the period included the incurrence of an incremental Term Loan B-2 tranche in the aggregate principal amount of $500 million and net draws on our revolving line of credit of $65 million. Significant uses of cash included regularly scheduled principal payments under our senior secured credit facilities totaling approximately $25 million on our Term Loan A-2 and $11 million on Term Loan B-2, as well as additional required payments under other debt arrangements. In addition, during the six months ended June 30, 2026 we used cash to repurchase 5.2 million shares of our common stock.
By comparison, the same period in 2025 included the issuance of the 6.75% Senior Notes in the amount of $1,000 million. Significant uses of cash included the repayment of $93 million in interest-free funding made available by UnitedHealth Group and its affiliates following the cybersecurity breach that affected Change Healthcare, a subsidiary of UnitedHealth Group, during the first quarter of 2024, regularly scheduled principal payments under our senior secured credit facilities totaling approximately $59 million on our Term Loan A-1 and $8 million on Term Loan B-1, and additional required payments under other debt arrangements. We also recognized financing cash outflows of $12 million in deferred financing costs related to the 6.75% Senior Notes transaction, as well as $13 million in cap premium fees for our 2025 forward interest rate cap agreements. In addition, during the six months ended June 30, 2025 we used cash to repurchase 6.7 million shares of our common stock.
Dialysis center footprint
The table below shows the footprint of our dialysis operations by number of dialysis centers owned or operated:
U.S.International
Six months ended June 30,
2026202520262025
Number of centers operated at beginning of period2,657 2,657 585 509 
Acquired centers8 2 13 1 
Developed centers4 9 2 6 
Net change in non-owned managed or administered centers(1)
3 — 2 4 
Sold and closed centers(2)
— (3)(5)(4)
Closed centers(3)
(1)(3)(2)(3)
Number of centers operated at end of period2,671 2,662 595 513 
(1)Represents the change in the number of dialysis centers which we manage or provide administrative services to but in which we own a noncontrolling equity interest or which are wholly-owned by third parties.
(2)Represents dialysis centers that were sold and/or closed for which the majority of patients were not retained.
(3)Represents dialysis centers that were closed for which the majority of patients were retained and transferred to one of our other existing outpatient dialysis centers.
Available liquidity
As of June 30, 2026, we had $1.435 billion available and $65 million drawn on our $1.5 billion revolving line of credit under our senior secured credit facilities. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were none as of June 30, 2026. We separately had approximately $188 million in letters of credit outstanding under a separate bilateral secured letter of credit facility.
See Note 6 to the condensed consolidated financial statements for components of our long-term debt and their interest rates.
We believe that our cash flow from operations and other sources of liquidity, including from amounts available under our senior secured credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months. From time to time, depending on market conditions, our capital requirements and the availability of financing, among other things, we may seek to refinance our existing debt and may incur additional indebtedness. Our primary recurrent sources of liquidity are cash from operations and cash from borrowings, which are subject to general, economic, financial, competitive, regulatory and other factors that are beyond our control, as described in Part I Item 1A. "Risk Factors" of our 2025 10-K.
33

Reconciliations of Non-GAAP measures
The following tables provide reconciliations of adjusted operating income (loss) to operating income (loss) as presented on a U.S. generally accepted accounting principles (GAAP) basis for our U.S. dialysis reportable segment as well as for our U.S. IKC business, our U.S. other ancillary services, our international business, and for our total ancillary services which combines them and is disclosed as our other segments category, in addition to our corporate administrative support.
These non-GAAP or "adjusted" measures are presented because management believes these measures are useful adjuncts to, but not alternatives for, our GAAP results. Specifically, management uses adjusted operating income (loss) to compare and evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe this non-GAAP measure is also useful to investors and analysts in evaluating our performance over time and relative to competitors, as well as in analyzing the underlying trends in our business. We also believe this presentation enhances a user's understanding of our normal operating income by excluding certain items which we do not believe are indicative of our ordinary results of operations.
In addition, our effective income tax rate on income attributable to DaVita Inc. excludes noncontrolling owners' income, which primarily relates to non-tax paying entities. We believe this adjusted effective income tax rate is useful to management, investors and analysts in evaluating our performance and establishing expectations for income taxes incurred on our ordinary results attributable to DaVita Inc.
Finally, our free cash flow represents net cash provided by operating activities less distributions to noncontrolling interests, development capital expenditures, and maintenance capital expenditures; plus contributions from noncontrolling interests and proceeds from the sale of self-developed properties. Management uses this measure to assess our ability to fund acquisitions and meet our debt service obligations and we believe this measure is equally useful to investors and analysts as an adjunct to cash flows from operating activities and other measures under GAAP.
It is important to bear in mind that these non-GAAP "adjusted" measures are not measures of financial performance under GAAP and should not be considered in isolation from, nor as substitutes for, their most comparable GAAP measures.
There were no non-GAAP adjustments during the three and six months ended June 30, 2026 or the three months ended March 31, 2026.
Six months ended June 30, 2025
U.S. dialysisAncillary servicesCorporate administrationConsolidated
U.S. IKCU.S. OtherInternationalTotal
(dollars in millions)
Operating income (loss)$999 $(3)$(10)$67 $54 $(76)$977 
Cybersecurity incident-related
 charges(1)
$13 — — — — — 13 
Adjusted operating income (loss)$1,012 $(3)$(10)$67 $54 $(76)$990 
Certain columns or rows in the above tables may not sum due to the presentation of rounded numbers.
(1)Represents charges recognized to remediate a cybersecurity incident and restore systems during the second quarter of 2025. We have excluded these charges from our non-GAAP metrics as we do not believe they are indicative of our ordinary results of operations. See additional discussion above under the heading "Cybersecurity incident-related charges" within "U.S. dialysis results of operations".

34

Three months endedSix months ended
June 30,
2026		March 31,
2026		June 30,
2026		June 30,
2025
(dollars in millions)
Income before income taxes$435 $341 $776 $655 
Less: Noncontrolling owners' income primarily attributable to non-tax paying entities(78)(78)(156)(146)
Income before income taxes attributable to DaVita Inc.$357 $264 $620 $510 
Income tax expense $92 $66 $158 $148 
Less: Income tax attributable to noncontrolling interests(1)— (1)— 
Income tax expense attributable to DaVita Inc.$91 $66 $157 $147 
Effective income tax rate on income attributable to DaVita Inc.25.6 %25.1 %25.4 %28.9 %
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.
Six months ended
June 30,
2026		June 30,
2025
(dollars in millions)
Net cash provided by operating activities$811 $504 
Adjustments to reconcile net cash provided by operating activities to free cash flow:
Distributions to noncontrolling interests(150)(151)
Contributions from noncontrolling interests4 3 
Maintenance capital expenditures(197)(185)
Development capital expenditures(75)(80)
Proceeds from sale of self-developed properties2 21 
Free cash flow$396 $112 
Certain columns or rows may not sum due to the presentation of rounded numbers.
Off-balance sheet arrangements and aggregate contractual obligations
In addition to the debt obligations and operating lease liabilities reflected on our balance sheet, we have certain potential commitments associated with letters of credit, working capital funding or other financing, if necessary, to certain nonconsolidated businesses that we manage and in which we own a noncontrolling equity interest or which are wholly-owned by third parties. We also have agreed to future investments in particular equity method and other investments if certain milestones are achieved or capital calls are made, as applicable. Additionally, see Note 14 to the condensed consolidated financial statements for discussion of the acquisition of a noncontrolling minority interest in Elara Caring, which closed effective July 20, 2026. For additional information, see Note 16 to the consolidated financial statements included in our 2025 10-K.
We also have potential obligations to purchase the noncontrolling interests held by third parties in many of our majority-owned dialysis partnerships and other nonconsolidated entities. These obligations are in the form of put provisions that are exercisable at the third-party owners’ discretion within specified periods as outlined in each specific put provision. For additional information on these obligations and how we measure and report them, see Note 11 to the condensed consolidated financial statements included in this report and Notes 16 and 23 to the consolidated financial statements included in our 2025 10-K.
For information on the maturities and other terms of our long-term debt and outstanding letters of credit, see Note 6 to the condensed consolidated financial statements.
As of June 30, 2026, we have outstanding purchase agreements with various suppliers to purchase set amounts of dialysis equipment, parts, pharmaceuticals, supplies and technology services. If we fail to meet the minimum purchase commitments under these contracts during any year, we are required to pay the difference to the supplier, as described further in Note 16 to the consolidated financial statements included in our 2025 10-K.
35

New Accounting Standards
See discussion of new accounting standards in Note 13 to the condensed consolidated financial statements.
Item 3.    Quantitative and Qualitative Disclosures about Market Risk
Interest rate and foreign currency sensitivity
There has been no material change in the nature of the Company's interest rate risks or foreign currency exchange risks from those described in Part II Item 7A, "Quantitative and Qualitative Disclosures about Market Risk" of our Annual Report on Form 10-K for the year ended December 31, 2025.
Item 4.    Controls and Procedures
Disclosure Controls and Procedures
As required by Exchange Act Rule 13a-15(b), our management, including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), conducted an evaluation of the effectiveness of our disclosure controls and procedures, as defined in Exchange Act Rule 13a-15(e), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of June 30, 2026.
Changes in Internal Control over Financial Reporting
In connection with the evaluation required by Exchange Act Rule 13a-15(d), our management, including our CEO and CFO, concluded that no changes in our internal control over financial reporting occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II.
OTHER INFORMATION
Item 1.    Legal Proceedings
The information required by this Part II, Item 1 is incorporated herein by reference to the information set forth under the caption "Commitments and contingencies" in Note 7 to the condensed consolidated financial statements included in this report.
Item 1A. Risk Factors
There have been no material changes to the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K (2025 10-K) for the year ended December 31, 2025 filed with Securities and Exchange Commission. You should carefully consider the risks included in our 2025 10-K, together with all the other information in this Quarterly Report on Form 10-Q, including the forward-looking statements in Part I, Item 2 of this Quarterly Report on Form 10-Q under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations."
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
Share repurchases
The following table summarizes our repurchases of our common stock during the second quarter of 2026:
PeriodTotal number
of shares
purchased
Average price paid per share(1)
Total number of shares
purchased as part of publicly announced plans or programs		Approximate dollar value of shares that may yet be purchased under the plans or programs
(dollars and shares in thousands, except per share data)
April 1-30, 2026786 $149.75 786 $1,638,550 
May 1-31, 20261,220 $149.84 1,220 $1,455,685 
June 1-30, 2026232 $199.55 232 $1,409,473 
2,238 $154.95 2,238 
(1)Excludes commissions and excise tax.
36

The Company is authorized to make share repurchases pursuant to prior Board authorizations. These authorizations allow the Company to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.
As of July 31, 2026, we had approximately $1,373 million, excluding excise taxes, available under current repurchase authorizations for additional share repurchases. Although these share repurchase authorizations do not have an expiration date, we remain subject to share repurchase limitations including under our current senior secured credit facilities.
Item 3.    Defaults Upon Senior Securities
None.
Item 4.    Mine Safety Disclosures
Not applicable.
Item 5.    Other Information
Director and Officer Trading Arrangements
None of the Company's directors or officers adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of SEC Regulation S-K) during the quarter ended June 30, 2026.
37

Item 6.    Exhibits
Exhibit
Number
10.1
Ninth Amendment, dated as of June 8, 2026, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent and swingline lender (including a conformed copy of the Credit Agreement, reflecting all amendments through the Ninth Amendment, attached as Annex A thereto).(1)
31.1
Certification of the Chief Executive Officer, dated August 4, 2026, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ü
31.2
Certification of the Chief Financial Officer, dated August 4, 2026, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ü
32.1
Certification of the Chief Executive Officer, dated August 4, 2026, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ü
32.2
Certification of the Chief Financial Officer, dated August 4, 2026, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ü
101.INS
XBRL Instance Document - the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. ü
101.SCH
Inline XBRL Taxonomy Extension Schema Document. ü
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document. ü
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document. ü
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document. ü
101.PRE
Inline XBRL Taxonomy Extension Presentation, Linkbase Document. ü
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). ü
üIncluded in this filing.
(1)Filed on June 8, 2026, as an exhibit to the Company's Current Report on Form 8-K
38

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
DAVITA INC.
BY:/s/   CHRISTOPHER M. BERRY
Christopher M. Berry
Chief Accounting Officer*
Date: August 4, 2026
 
 *Mr. Berry has signed both on behalf of the Registrant as a duly authorized officer and as the Registrant’s principal accounting officer.


39

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

© 2025 CompaniesMarketcap.com